documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead sciences truvada viread emtriva hepsera ambisome vistide letairis atripla registered trademark belonging bristolmyers squibb gilead sciences llc macugen registered trademark belonging osi pharmaceuticals inc sustiva registered trademark bristolmyers squibb company tamiflu registered trademark belonging f hoffmannla roche ltd flolan volibris registered trademarks glaxosmithkline inc report also includes trademarks service marks trade names companiestable contents annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning risks uncertainties assumptions referred may include limited following ability maintain continue increasing sales hiv products ability commercialize new products expand indications existing products significant competition face significant safety issues may arise marketed products product candidates ability comply complex us food drug administration fda comparable international regulations results anticipated timelines clinical trials uncertain may support continued development product pipeline reliance thirdparty contract research organizations conduct clinical trials inability directly control timing conduct expense quality clinical trials ability obtain materials supplies necessary conduct clinical trials manufacture sell products dependence relationships companies sales marketing performance revenues ability protect patents intellectual property rights domestically internationally ability operate without infringing upon patents proprietary rights third parties risk factors listed time time filings us securities exchange commission sec given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations sec undertake specifically decline obligation update statements publicly announce results revisions forward looking statements distribution report whether result new information future events changes assumptions otherwise table contents part item business overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california operations north america europe australia date focused efforts bringing novel therapeutics treatment lifethreatening diseases market continue seek add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy products truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat human immunodeficiency virus hiv infection adults fixeddose combination antihiv medications viread tenofovir disoproxil fumarate emtriva emtricitabine promote truvada united states us commercial team sell united states exclusively wholesale channel promote sell truvada europe commercial team distributors australia new zealand commercial team certain latin american middle eastern asian countries distributors promote sell truvada japan corporate partner japan tobacco inc japan tobacco addition truvada made available us substantially reduced prices certain developing world countries included gilead access program atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dosed day treatment hiv infection adults atripla first oncedaily single tablet regimen hiv intended standalone therapy combination antiretrovirals fixeddose combination antihiv medications viread emtriva bristol myerssquibb companys sustiva efavirenz promote atripla joint venture partner bristol myerssquibb company bms united states companys commercial teams sell joint venture bristol myerssquibb gilead sciences llc united states exclusively wholesale channel atripla approved sale european union december currently sold united kingdom germany austria plan promote atripla jointly bms majority countries europe responsible selling distributing product countries limited number central eastern european countries either bms thirdparty distributor sole promoting selling distributing company addition make atripla available substantially reduced prices certain developing world countries collaboration merck co inc merck viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults promote viread united states us commercial team sell united states exclusively wholesale channel promote sell viread europe commercial team distributors australia new zealand commercial team certain latin american middle eastern asian countries distributors promote sell viread japan corporate partner japan tobacco addition viread made available us substantially reduced prices certain developing world countries included gilead access program emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also approved part combination therapy treat hiv infection children promote table contents emtriva united states us commercial team sell united states exclusively wholesale channel promote sell emtriva europe commercial team distributors australia new zealand commercial team certain latin american middle eastern countries distributors promote sell emtriva japan corporate partner japan tobacco hepsera adefovir dipivoxil oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dosed day treat chronic hepatitis b hepsera approved sale united states treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team promotes hepsera united states sell united states exclusively wholesale channel promote sell hepsera europe commercial team distributors australia new zealand commercial team licensed rights commercialize hepsera solely treatment hepatitis b asia latin america certain territories glaxosmithkline inc gsk ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species corporate partner astellas pharma inc astellas promotes sells ambisome united states canada promote sell ambisome europe australia new zealand commercial team distributors also use various distributors promote sell ambisome certain latin american middle eastern asian countries including india excluding japan dainippon sumitomo pharma co ltd responsible promotion distribution letairis ambrisentan endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening letairis approved united states june available special restricted distribution program called letairis education access program leap prescribers pharmacies registered leap may prescribe sell distribute letairis letairis granted orphan drug status treatment pah united states well european union recently received positive opinion european committee human medicinal products treatment pah marketed name volibris gsk upon approval exclusive license patent rights related technology letairis united states abbott laboratories inc abbott sublicensed gsk rights letairis certain hypertensive conditions territories outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patients aids vistide approved sale united states sell product exclusively wholesale channel countries outside united states vistide sold pfizer inc pfizer flolan epoprostenol sodium injected medication longterm intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease new york heart association class iii class iv patients respond adequately conventional therapy license agreement distribution supply agreement gsk exclusive rights market promote distribute flolan sterile diluent flolan united states april flolan distributed united states specialty pharmacy table contents following table lists aggregate product sales major products thousands total total total product product product sales sales sales hiv products truvada atripla viread emtriva total hiv products hepsera ambisome total product sales see item note consolidated financial statements pages included annual report total revenues geographic area royalties products tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors tamiflu approved treatment influenza children adults countries including united states japan european union approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture third parties sell tamiflu worldwide subject obligation pay us royalties based percentage net sales roche generates sale tamiflu worldwide macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen approved fda united states december sales commenced january february product received marketing approval sale european union macugen developed osi pharmaceuticals inc osi using technology licensed us promoted united states osi osi holds exclusive rights manufacture sell macugen united states pfizer holds exclusive right manufacture sell macugen rest world receive royalties osi based sales macugen worldwide commercialization distribution us international commercial sales operations marketing subsidiaries australia austria canada france germany greece ireland italy new zealand portugal spain switzerland turkey united kingdom united states process establishing marketing subsidiaries belgium denmark finland netherlands norway sweden intend terminate distributor agreements covering territories commercial teams promote truvada viread emtriva hepsera ambisome letairis flolan direct field contact physicians hospitals clinics healthcare providers table contents sell distribute truvada viread emtriva hepsera vistide united states exclusively wholesale channel corporate partner astellas promotes sells distributes ambisome united states letairis flolan sold distributed exclusively specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling letairis available leap special restricted distribution program sell distribute truvada viread emtriva hepsera ambisome europe either commercial team thirdparty distributors australia new zealand commercial team sell distribute truvada viread emtriva hepsera ambisome countries outside united states europe including countries asia latin america middle east australia new zealand africa territories exception australia new zealand enter agreements thirdparty distributors granting exclusive right sell products particular territory specified period time agreements provide collaborative efforts distributor us obtaining regulatory approval product specified territory agreements generally grant distributor right promote product territory promote atripla united states joint venture partner bms respective commercial teams using direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv atripla approved sale european union december currently sold united kingdom germany austria plan promote atripla jointly bms majority countries europe responsible selling distributing product countries limited number central eastern european countries either bms thirdparty distributor sole promoting selling distributing company smaller group noneuropean union eastern central european countries atripla promoted bms either directly thirdparty distributors product sales three large wholesalers accounting total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total revenues following table summarizes percent total revenues attributed product sales made three wholesalers year ended december cardinal health inc mckesson corp amerisourcebergen corp competition products development programs target number areas including viral fungal respiratory cardiovascular diseases many commercially available products treatment diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases products compete available products based primarily efficacy safety tolerability table contents acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development approximately branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudine zidovudine epzicomkivexa abacavir lamivudine trizivir abacavirlamivudinezidovudine sold gsk companies hiv products competing nrti class include bms roche although hiv products also compete broadly hiv products boehringer ingelheim gmbh merck abbott tibotec therapeutics division ortho biotech products lp bmss videx ec didanosine ddi became first generic hiv product united states gsks retrovir zidovudine also faces generic competition united states result launch generic zidovudine date little impact generic didanosine generic zidovudine price hiv products however price decreases hiv products may result longer term ambisome ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association hepsera hepsera faces significant competition existing expected therapies treating patients chronic hepatitis b hepsera faced increased competition baraclude entecavir oral nucleoside analogue developed bms launched united states tyzekasebivo telbivudine oral nucleoside analogue developed novartis pharmaceuticals corporation novartis sale united states european union china also competes epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia table contents hepsera also competes established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment chronic hepatitis b letairis letairis competes directly tracleer bosentan sold actelion ltd indirectly pah products united therapeutics corporation pfizer vistide vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision flolan flolan competes primarily remodulin treprostinil form prostacyclin administered via continuous subcutaneous infusion continuous intravenous infusion sold united therapeutics corporation united states flolan also competes ventavis iloprost inhaled form prostacyclin sold affiliates actelion ltd united states addition patent covering flolan expired one generic pharmaceutical companies may launch generic version flolan united states tamiflu tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trials macugen macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future existing future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover investments resources used develop products collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including financial accounting impact business found item note consolidated financial statements pages included annual report table contents commercial collaborations following list representative commercial collaborations year commercial collaboration partner product signing astellas ambisome iocbrega truvada atripla viread hepsera vistide emory truvada atripla emtriva roche tamiflu pfizer vistide macugen sumitomo ambisome osi macugen abbott letairis gsk hepsera letairis flolan japan tobacco truvada viread emtriva bms atripla astellas pharma inc astellas entered agreement astellas successor fujisawa usa inc related rights market ambisome agreement astellas responsible promoting ambisome united states canada exclusive marketing rights ambisome rest world subject obligation pay royalties astellas connection sales significant markets asia including china india japan south korea taiwan astellas collects payments sale ambisome united states canada subject obligation pay us royalties astellass gross profits sale ambisome united states canada institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega entered agreements iocbrega relating certain nucleotide compounds discovered two institutions agreements received exclusive right manufacture use sell nucleotide compounds obligated pay iocbrega percentage net sales received sales products containing patented compounds subject minimum royalty payments compounds covered original agreements include cidofovir active pharmaceutical ingredient vistide adefovir active pharmaceutical ingredient hepsera tenofovir active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla december agreements iocbrega amended provide reduced royalty rate future sales product incorporating adefovir tenofovir return upfront payment us upon signing amendment august iocbrega agreed waive right royalty sales truvada viread developing countries sell products substantially reduced prices gilead access program sales atripla distributed merck developing countries august executed amendment agreements iocbrega sets forth royalty obligations sales products containing tenofovir certain upper lower middleincome countries sales products containing tenofovir manufactured indian generic companies certain specified developing countries including india emory university emory april obtained exclusive worldwide license emorys rights purified forms emtricitabine active pharmaceutical ingredient emtriva table contents component truvada atripla use treatment hiv hbv prior july paid royalties emory worldwide net sales product containing emtricitabine july royalty pharma purchased respectively royalty interest owned emory exchange elimination emtricitabine royalties payable emory since july paid royalties worldwide net sales products containing emtricitabine directly royalty pharma rate proportional share purchase price also july made payment emory connection amendment restatement existing license agreement emory pertained obligation develop emtricitabine hepatitis b indication f hoffmannla roche ltd together hoffmannla roche inc roche september entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales november entered first amendment supplement original agreement roche amendment eliminated cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also provided formation joint manufacturing committee review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives roche us amendment option provide specialized sales force supplement roches us marketing efforts tamiflu exercised date pfizer inc pfizer august granted pfizer exclusive right market sell vistide countries outside united states subject payment us percentage net product sales vistide pfizer agreement required sell pfizer bulk cidofovir maintain vistide patents connection agreement received upfront license fee milestone payment upon obtaining marketing approval europe entitled receive certain royalties net sales vistide december osi granted pfizer sublicense relating macugen connection sublicense entered license pfizer terms contained agreement osi dainippon sumitomo pharma co ltd sumitomo september entered agreement sumitomo successor sumitomo pharmaceuticals co ltd pursuant sumitomo agreed develop market ambisome japan agreement amended restated august terms restated agreement received upfront license fee certain milestone payments entitled receive royalties ambisome sales japan agreement required supply sumitomo unlabeled vials ambisome sumitomo package label market distribute japan osi pharmaceuticals inc osi march granted osi worldwide rights therapeutic uses macugen osi sublicensed rights macugen territories outside united states pfizer entered license agreement pfizer terms contained agreement osi entitled receive payments osi osi reaches certain milestones well royalties worldwide net sales macugen subject obligations make payments third parties relating royalties december entered agreement osi fill finish macugen osi abbott laboratories inc abbott october abbott granted us exclusive worldwide license develop commercialize ambrisentan active pharmaceutical ingredient letairis therapeutic uses agreement required make certain milestone payments well pay royalties based net sales letairis june fda approved letairis table contents treatment pah united states march discussed sublicensed glaxosmithkline inc rights ambrisentan certain hypertensive conditions territories outside united states glaxosmithkline inc gsk april granted gsk right commercialize hepsera solely treatment chronic hepatitis b asia latin america certain territories significant include china japan south korea taiwan agreement retained rights hepsera united states canada europe australia new zealand turkey received upfront license fee milestone payments payable licensing agreement gsk full responsibility development commercialization hepsera treatment hepatitis b territories addition gsk required pay us royalties net sales hepsera gsks hepatitis product epivirhbvzeffix gsk territories hepsera launched japan south korea taiwan china march exclusively sublicensed gsk rights ambrisentan active pharmaceutical ingredient letairis certain hypertensive conditions territories outside united states license agreement received upfront payment subject achievement specific milestones eligible receive additional milestone payments addition receive royalties based net sales letairis gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses letairis gsk territories term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop letairis new indications licensed field party pay share external costs associated joint development march received milestone payment gsk validation european medicines agency marketing authorization application letairis treatment pah march entered license agreement distribution supply agreement gsk exclusive rights promote sell distribute flolan sterile diluent flolan united states april addition gsk assigned us rights responsibilities respect flolan certain agreements specialty pharmacy distributors extent gross sales flolan united states exceed certain predefined targets supply price paid us gsk flolan decrease sliding scale commenced distribution activities flolan united states distribution supply agreement april japan tobacco inc japan tobacco july entered licensing agreement japan tobacco japan tobacco would commercialize certain hiv products specifically viread truvada emtriva japan terms agreement received upfront license fee additional cash payments upon achievement certain milestones japan tobacco also required pay us royalty net sales products japan march viread approved sale japan march emtriva truvada approved sale japan bristolmyers squibb company bms december entered collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approved use united states july sold name atripla bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royaltyfree sublicenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable truvada emtricitabine tenofovir disoproxil table contents fumarate sustiva efavirenz respectively since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees formed bms us responsible accounting financial reporting tax reporting product distribution joint venture september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada december entered collaboration bms sets forth terms conditions bms commercialize atripla european union norway iceland switzerland liechtenstein either bms thirdparty distributor act selling party countries responsible among things receiving processing customer orders warehousing product collecting sales handling returns manufacturing atripla coordinated us primarily responsible distribution logistics general parties share revenues outofpocket expenses proportion net selling prices truvada emtricitabine tenofovir disoproxil fumarate respect us efavirenz respect bms access developing world gilead access program established make truvada viread available substantially reduced prices countries developing world developed system tiered pricing reflects economic status using gross national incomegniper capita disease prevalence low lower middleincome countries approach allows us price therapies based countrys ability pay example higher prevalence exists certain country country also relatively high gni country would moved lower price tier accommodate higher burden disease also support many clinical studies donation products help define best treatment strategies developing world studies support include dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart development antiretroviral therapy study aimed studying clinical versus laboratory monitoring practices structured treatment interruptions continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis exists clinical trial conducted institute one world health partnership world health organization also entered number collaborations developing world include aspen pharmacare holdings ltd aspen october entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada certain developing world countries included gilead access program november amended agreement aspen amended agreement aspen retained right manufacture distribute viread truvada certain developing world countries gilead access program aspen right purchase viread truvada britestock form us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers table contents approved us aspen also granted option manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate meet certain regulatory standards upon executing amended agreement aspen notified us intend exercise option manufacture distribute generic products certain developing world countries aspen required pay us royalties net sales viread truvada generic versions emtricitabine tenofovir disoproxil fumarate manufactured distributed aspen generic licenses entered nonexclusive license agreements ten indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate lowincome countries around world included india many lowincome countries gilead access program agreements require generic manufacturers meet certain national international regulatory standards include technology transfer enable expeditious production large volumes highquality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product merck august entered agreement affiliate merck pursuant provide atripla substantially reduced prices hivinfected patients developing countries africa caribbean latin america southeast asia utilizing different trade dress us european tablets agreement manufacture atripla using efavirenz supplied merck merck handle distribution product countries covered agreement international partnership microbicides ipm conrad december entered agreement granted rights ipm conrad cooperating agency us agency international development usaid committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resourcelimited countries tenofovir microbicide prevent hiv infection research collaborations following list representative research collaborations research collaboration partner program area year signing university texas system novel compounds treatment cardiac hypertrophy heart disease heart failure well fibrosis respiratory pulmonary diseases abbott laboratories darusentan treatment certain hypertensive conditions novartis institutes novel compounds treatment cardiovascular disease novartis vaccines small molecule therapeutics certain hepatitis c virus hcv drug targets genelabs nucleoside rna polymerase inhibitors treatment hcv achillion compounds treatment hcv japan tobacco elvitegravir also known gs treatment hiv parion p gs epithelial sodium channel enac inhibitor treatment pulmonary diseases lgls caspase inhibitors treatment fibrotic diseases university texas system december entered license agreement university texas system granting us exclusive rights certain patents technology related cardiac hypertrophy heart disease heart failure concurrently entered sponsored research table contents agreement university fund research cardiac hypertrophy heart failure university texas southwestern medical center november amended restated sponsored research agreement extend term research collaboration march expand scope research collaboration include research relating fibrosis respiratory pulmonary diseases increase amount funding providing sponsored research concurrently amended restated license agreement provide us right license inventions arising sponsored research conducted amended restated sponsored research agreement obligated pay certain annual fees well percentage sublicense revenue royalties based upon net sales additionally obligated make milestone payments products developed licensed technology january entered second license agreement amended february november related sponsored research agreement university texas system also amended may november amended agreements received exclusive rights certain patents technology relating cardiac hypertrophy heart disease heart failure including inventions arose conduct sponsored research research conducted sponsored research agreement completed obligation pay milestone payments plus percentage sublicense revenue royalties based upon percentage net sales products covered license agreement abbott june entered exclusive worldwide license agreement abbott develop commercialize darusentan conditions except oncology obligated make future milestone payments well pay royalties based net sales successfully commercialize drug indication commercialize darusentan certain markets abbott may market product affected markets pay us royalty sales darusentan currently studied phase clinical trials treatment patients resistant hypertension novartis institutes biomedical research inc novartis institutes october entered research collaboration novartis institutes discovery development novel drugs treatment cardiovascular disease novartis institutes provides research funding us exchange rights license compounds developed collaboration may collaboration expanded include histone deacetylase inhibitor hdaci program acquired myogen inc myogen novartis institutes exclusive option license discoveries relevant field limited exceptions may relating hdaci product candidates october relating product candidates hdaci product candidates upon execution license product candidate novartis institutes obligated fund development product candidate make payments us upon achievement certain milestones pay us royalties sales product successfully commercialized date novartis institutes licensed drug targets compounds terms collaboration novartis vaccines diagnostics inc novartis vaccines august entered nonexclusive licensing agreement novartis vaccines successor chiron corporation research development commercialization small molecule therapeutics selected hcv drug targets agreement received nonexclusive rights use novartis vacciness hcv technology develop commercialize products treatment hcv terms agreement paid novartis vaccines upfront license fee agreed make additional payments certain clinical regulatory contractually determined milestones met additionally obligated make royalty payments event product developed using licensed technology genelabs technologies inc genelabs september entered license research collaboration agreement genelabs research develop commercialize certain genelabss novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing agreement paid upfront license fee agreement table contents provided would support ongoing research nucleoside hcv inhibitors genelabs fund fulltime equivalents three year term expired september currently selecting certain inhibitors development obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration achillion pharmaceuticals inc achillion november entered exclusive license collaboration agreement achillion pursuant agreement granted worldwide rights research development commercialization certain small molecule hcv replication inhibitors involving hcv protease treatment hepatitis c infection collaboration achillion obligated continue development inhibitor compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofof concept shared equally achillion us contractually agreed upon budget following proofofconcept study obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration paid upfront license fee made certain investments achillions equity also agreed make payments achillion upon achievement certain milestones outlined agreement pay royalties future net sales products arising collaboration december achillion began dosing hcvinfected patients phase clinical study gs also known ach treatment hepatitis c infection february based preliminary data phase b study companies decided discontinue development gs two companies continue explore nsa antagonists discovered achillion gilead taking lead future preclinical clinical development work appropriate candidate identified japan tobacco march entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor also known gs countries world excluding japan japan tobacco would retain rights terms agreement paid upfront license fee milestone payment additionally obligated make additional cash payments upon achievement certain milestones well pay royalties based net sales territories market product parion sciences inc parion august entered exclusive licensing codevelopment agreement parion focused p gs epithelial sodium channel enac inhibitor discovered parion agreement granted us worldwide commercialization rights gs treatment pulmonary diseases including cystic fibrosis cf chronic obstructive pulmonary disease noncf bronchiectasis addition parion collaborate research program identify promising enac blockerbased drug candidates utilizing parions proprietary enacbased chemistry platform terms agreement paid parion upfront payment addition obligated provide research funding pay parion royalties based potential future products sales make cash payments upon achievements certain milestones lg life sciences ltd lgls november entered exclusive license agreement lgls focused development caspase inhibitors treatment fibrotic diseases agreement granted us commercialization rights lglss caspase inhibitors including lb known gs gs investigational caspase inhibitor currently evaluated phase clinical trial patients chronically infected hcv agreement also obligated us fund collaborative research program two years identify potential caspase inhibitor drug candidates terms agreement paid lgls front license payment obligated fund additional research pay lgls royalties based net product sales may also obligated make milestone payments upon achievement certain development regulatory table contents commercial objectives license worldwide exception korea china india lgls retained rights lgls also retained right develop commercialize caspase inhibitors ophthalmic topical uses worldwide research development addition entering collaborations companies universities medical research institutions seek add existing portfolio products internal discovery clinical development programs active inlicensing product acquisition strategy acquisitions myogen corus pharma inc research scientists foster city san dimas california durham north carolina seattle washington westminster colorado engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs internal research focused discovery development treatments diseases following areas hiv february completed phase study elvitegravir also known gs novel integrase inhibitor hiv licensed japan tobacco discussions fda european medicines evaluation agency emea concerning design phase program pending positive outcome discussions hope dose first patients phase clinical study elvitegravir third quarter completed phase single dose pharmacokinetic study gs healthy volunteers gs novel nucleotide analog designed deliver high intracellular concentrations active molecule allowing lower doses higher potency results phase study confirmed preclinical results delivery high intracellular concentrations compound low doses gs result pending discussions fda design phase protocol anticipate dosing first patients phase study evaluating gs treatmentexperienced hiv infected patients confirmed nrti resistance first half hepatitis hbv november presented positive results two phase pivotal studies comparing efficacy safety tenofovir disoproxil fumarate active pharmaceutical ingredient viread versus hepsera patients chronic hepatitis b based data october filed supplemental new drug application nda fda well type ii variation emea marketing approval viread treatment chronic hepatitis b adults hcv november released preliminary phase ab data single dose first two doses sevenday treatment course gs novel nonnucleoside polymerase inhibitor data demonstrated favorable antiviral activity pharmacokinetics exposure doses evaluated study also observed possible qt prolongation mg dose measure cardiovascular safety conducted completed pilot qt study healthy volunteers mg mg doses confirmed qt prolongations mg dose prolongations mg dose small believe clinically manageable therefore seeking fdas consent reinitiate dosing hcvinfected individuals define efficacy safety compound also hcv november entered exclusive license agreement lgls focused development caspase inhibitors treatment fibrotic diseases agreement granted us commercialization rights lglss caspase inhibitors including gs lglss lead compound formerly called lb gs investigational table contents caspase inhibitor currently evaluated phase clinical trial patients chronic hepatitis c anticipate data trial end addition research collaborations achillion genelabs continue hope development candidates emerge efforts respiratory cardiovascular diseases respiratory area october presented data second two pivotal phase studies aztreonam lysine inhalation inhaled antibiotic treatment patients cf pulmonary infection pseudomonas aeruginosa p aeruginosa november submitted nda fda marketing approval aztreonam lysine inhalation mg three times daily treatment pulmonary p aeruginosa infection people cf based discussions emea plan submit marketing authorization application second quarter october also presented data gs proprietary inhaled formulation tobramycin fosfomycin demonstrating compounds activity pathogens commonly found patients cf bronchiectasis based preclinical study results initiated completed single phase study healthy volunteers began enrolling patients either cf bronchiectasis phase b study third quarter cardiovascular area conducting two phase clinical studies darusentan treatment resistant hypertension program obtained myogen acquisition expect complete enrollment receive data studies addition research collaborations university texas novartis institutes continue seek identify development candidates treatment cardiovascular disorders face numerous risks uncertainties product candidates including listed risks include challenges clinical trial protocol design ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates programs others pipeline completed timely basis prospects future revenue growth may adversely impacted total research development expenses million compared million million patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents table contents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us patent european patent products expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread emtriva truvada atripla patents covering active pharmaceutical ingredients truvada atripla viread emtriva hepsera letairis vistide held third parties acquired exclusive rights patents agreements parties see commercial collaborations patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera applications pending various countries asia including china relate specific forms formulations hepsera asia major market therapies hepatitis b infection indication hepsera developed patent covering flolan held third party market exclusivity protection expired result one generic pharmaceutical companies may launch generic version flolan united states may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents vistide granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license alternative technologies may unable develop commercialize products business could adversely affected example aware body patents may relate operation leap restricted distribution program designed support letairis evaluating patents relevance leap patent applications confidential least period time patent issued may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block table contents compete patents competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection example march public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient truvada atripla viread pto granted requests july pto issued nonfinal rejections four patents step common reexamination proceeding initiate reexamination process predict ultimate outcome office actions unsuccessful responding office actions original claims patents may narrowed invalidated pto narrows invalidates patents may cause similar organizations seek reexamination proceedings challenging patents foreign jurisdictions pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developed developing addition certain countries africa asia including china permit enforcement patents manufacturers able sell generic versions products countries part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated nda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions august pto adopted new rules scheduled become effective november october gsk successfully obtained preliminary injunction implementation rules rules include limitations number claims permitted patent application number continuing patent applications filed rules implemented may limited table contents ability obtain broad patent coverage products product candidates may allow competitors market products similar obtain patent coverage closely related products manufacturing raw materials antiviral products contract third parties manufacture antiviral products clinical commercial purposes including truvada atripla viread emtriva hepsera vistide historically manufactured antiviral products commercial scale however result acquisition raylo chemicals inc subsidiary germanybased specialty chemicals company degussa ag november began produce quantities tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla emtricitabine active pharmaceutical ingredient emtriva one active pharmaceutical ingredients truvada atripla edmonton alberta canada facility also utilize site process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational products chemical development activities improve existing commercial manufacturing processes continue use multiple thirdparty contract manufacturers manufacture additional quantities tenofovir disoproxil fumarate emtricitabine manufacture adefovir dipivoxil active pharmaceutical ingredient hepsera cidofovir active pharmaceutical ingredient vistide use multiple thirdparty contract manufacturers tablet truvada atripla viread emtriva hepsera manufacturers qualified approved supply product united states european union markets emtriva capsulation also completed thirdparty contract manufacturers use single thirdparty manufacturer supply vistide fill package drug product truvada atripla viread emtriva hepsera finished forms facilities san dimas california near dublin ireland september acquired nycomed limited wholly owned irish subsidiary germanybased pharmaceutical company nycomed gmbh transferred certain operations dublin ireland area site facility located cork ireland utilize site primarily solid dose tablet manufacturing certain antiviral products well product packaging activities roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu future antiviral products continue consider developing additional manufacturing capabilities establishing additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct large scale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products us agreements manufacturers intended restrict manufacturers using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products could required enter table contents additional agreements manufacturers wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable us ambisome manufacture ambisome commercial quantities fdaapproved facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome facilities import ambisome european union manufacturing facility near dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain cholesterol use manufacture ambisome single approved supplier ambisome sold freezedried product given current projections ambisome demand believe sufficient production capacity san dimas facility meet future demand also option installing additional freezedrying capacity san dimas additional requirements become necessary letairis manufacture active pharmaceutical ingredient letairis exclusively edmonton alberta facility although another thirdparty supplier qualified make active pharmaceutical ingredient letairis rely single thirdparty supplier tablet letairis flolan gsk affiliates third parties manufacture flolan distribution us united states terms distribution supply agreement gsk macugen manufacture macugen commercial quantities facilities san dimas manufacturing agreements osi pfizer currently osi provides pegaptanib sodium active pharmaceutical ingredient macugen based osis pfizers current projections macugen demand believe sufficient production capacity meet future demand seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented total revenues tamiflu royalties comprised significant portion affected seasonality royalty revenue recognize roches sales tamiflu impacted severity associated flu seasons product delivery response avian influenza pandemic threat part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal table contents food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind application study drug candidate human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form nda snda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate could stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit table contents fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive postmarketing testing surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas foster city facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv designated use presidents emergency plan aids relief may also qualify expedited priority review viread truvada atripla received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures pricing reimbursement approvals also required countries pricing reimbursement successful commercialization products depends part availability governmental thirdparty payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average selling prices example majority sales truvada atripla viread hepsera ambisome letairis vistide subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase pricing pressures united states internationally pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general table contents legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited initially patients transitioning medicaid medicare part longer term impact new law business yet clear us impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category entities providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients results operations could materially adversely affected reimbursement changes emerging medicare prescription drug coverage legislation addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules additionally health care reform federal state levels could adversely affect payment drugs time states already enacted health care reform legislation europe success truvada atripla viread emtriva hepsera ambisome also depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months also expect success product candidates particularly europe depend ability obtain reimbursement product candidates commercialized even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase new drugs come market may face significant price decreases products across european countries believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth health care fraud abuse laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment thirdparty payors including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws violations fraud abuse laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could material adverse effect results operations table contents november received subpoena united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva complying us attorneys subpoena intend cooperate related government investigation compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread result discussions brazilian government reached agreement brazilian health ministry may reduce price viread brazil approximately addition concerns cost availability tamiflu related potential avian flu pandemic generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing leastdeveloped countries canadas access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment seek comply applicable statutory administrative requirements concerning environmental quality made continue make expenditures environmental compliance protection expenditures compliance environmental laws expected material effect capital expenditures results operations competitive position information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically table contents mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request item risk factors evaluating business carefully consider following risks addition information annual report following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales limited number products unable maintain continue increasing sales hiv products results operations may adversely affected currently dependent sales products treatment human immunodeficiency virus hiv infection especially truvada atripla support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts hiv product sales year ended december billion total revenues sales truvada atripla accounted respectively total hiv product sales year ended december may able continue growth rate sales hiv products reasons stated risk factor section particular following reasons hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing may affected substantial portion pretax income derived royalty revenue recognized sales tamiflu roche sales tamiflu decrease pretax income disproportionately affected f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu worldwide treatment prevention influenza royaltypaying collaborative agreement us recognized million royalty revenue year ended december related royalties table contents received fourth quarter first three quarters sales tamiflu roche although royalty revenue represented less total revenues represented pretax income period roches tamiflu sales unpredictable variability due strong relationship global pandemic planning efforts sales tamiflu declined sharply second half due fulfillment existing pandemic stockpiling orders governments corporations roche recently reported expects significant decrease tamiflu sales sales tamiflu decrease royalty revenue decrease pretax income decrease disproportionately decrease could material fail commercialize new products expand indications existing products prospects future revenues stock price may adversely affected introduce new products increase revenues existing products able increase maintain total revenues new product commercialization effort including letairis treatment pulmonary arterial hypertension pah launched united states june face risks outlined section fail increase sales products bring new products market may able increase revenues expand rd efforts example new drug application nda submitted us november aztreonam lysine inhalation treatment cystic fibrosis cf marketing authorization applications submitted us october viread treatment chronic hepatitis b united states european union may granted timelines currently anticipated december committee medicinal product human use european medicines agency emea granted marketing authorization atripla european union treatment hiv infection adults virologic suppression hiv rna levels less copiesml current combination antiretroviral therapy three months patients must experienced virological failure prior antiretroviral therapy must known harbored virus strains mutations conferring significant resistance three components contained atripla restriction atriplas use european union prevent us promoting atripla use patients previously achieved reduction viral load use antiretroviral therapy including newly diagnosed patients seek expand indication atripla european union emea may require us perform additional clinical trials may unable complete unable expand indication atripla include broader population patients impact future sales atripla european union unknown could limited markets including united states restrictions addition sales atripla may increase expense product sales component products overall total revenues may increase atripla sales increase face numerous risks uncertainties product candidates including elvitegravir novel hiv integrase inhibitor also known gs darusentan treatment resistant hypertension currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain united states food drug administration fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted table contents face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products glaxosmithkline inc gsk markets fixeddose combination products compete truvada atripla hepsera encountered increased competition baraclude entecavir bristolmyers squibb company bms tyzekasebivo telbivudine novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck co inc merck pfizer inc pfizer addition aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly actelion pharmaceuticals us incs tracleer bosentan indirectly pah products united therapeutics corporation pfizer aztreonam lysine inhalation treatment cf approved marketing compete tobi tobramycin inhalation marketed novartis viread treatment hepatitis b virus approved marketing compete hepsera current product treatment chronic hepatitis b hepsera well baraclude entecavir tyzekasebivo telbivudine significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases limited post approval use products used longer periods time many patients taking numerous medicines many underlying health problems expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products safety efficacy studies viread emtriva dosed separate products ongoing underway longer period time safety efficacy studies truvada viread emtriva together also underway also conducting similar studies atripla truvada sustiva together addition product letairis approved fda june member new class compounds called endothelin receptor antagonists pose specific risks including serious risks liver injury birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product example since launch letairis cases edema certain patients taking letairis reported information recently added product label may negatively impact demand product serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials truvada atripla viread emtriva hepsera ambisome letairis table contents currently approved additional uses anticipate file marketing approval additional countries additional products next several years products may fail receive marketing approval timely basis addition marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution september president bush signed law food drug administration amendments act fdaaa created significant additions fdas authority fdaaa expanded fdas authority among things require sponsors marketed products conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk mandate labeling changes products point products lifecycle based new safety information require sponsors implement risk evaluation mitigation strategy product could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply new requirements imposed sponsor fda could result significant civil monetary penalties results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example observed possible qt prolongation measure cardiovascular safety phase ab study novel nonnucleoside polymerase inhibitor also known gs result conducted pilot qt study healthy volunteers mg mg bid doses qt prolongations confirmed mg dose prolongations mg dose small believe clinically manageable seeking fdas consent reinitiate dosing hcvinfected individuals define efficacy safety compound delayed development compound unable obtain fdas consent reinitiate dosing program may delayed may decide cease efforts commercialize compound addition may face challenges clinical trial protocol design example discussions fda european medicines evaluation agency concerning design phase clinical studies elvitegravir novel hiv integrase inhibitor also known gs results discussions positive clinical trials elvitegravir may completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business table contents due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros control perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted february advised fda discovered certain irregularities inspection bioanalytical analyses conducted various organizations one thirdparty cros period review cro performed bioanalytical analyses studies certain products know whether investigation involves impact clinical data results related regulatory approvals manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis truvada atripla viread emtriva hepsera letairis vistide addition roche either third parties responsible manufacturing tamiflu manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers subject fdas current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing recordkeeping quality standards similar regulations effect countries manufacturing operations also subject routine inspections regulatory agencies additionally thirdparty manufacturers independent entities subject unique operational financial risks control thirdparty manufacturers fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected ability successfully manufacture commercialize aztreonam lysine inhalation approved depend upon ability continue manufacture multiproduct facility aztreonam lysine monobactam gramnegative antibiotic currently plan manufacture third parties multiproduct manufacturing facility historically fda permitted manufacture monobactams multiproduct manufacturing facilities however assurances fda continue allow practice currently singleproduct facility dedicated manufacture aztreonam lysine inhalation engaged contract manufacturer singleproduct facility aztreonam lysine inhalation fda prohibits manufacture monobactam antibiotics like aztreonam lysine inhalation multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies aztreonam lysine inhalation anticipated financial results attributable product approved may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues need access certain supplies products conduct clinical trials inability obtain materials timely manner may delay development efforts product candidates could limit ability generate revenues table contents suppliers key components materials must named nda filed fda product candidate significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs addition depend single supplier high quality cholesterol used manufacture ambisome also depend single suppliers active pharmaceutical ingredient tableting letairis product candidate aztreonam lysine inhalation pending fda approval administered lungs patients device made single supplier single site plan seeking fda approval manufacture aztreonam lysine inhalation facilities san dimas currently rely single thirdparty supplier manufacture aztreonam lysine inhalation guarantee fda approve facility manufacture aztreonam lysine inhalation timely manner addition aware thirdparty supplier gmp compliance issues resulted issuance approvable letters fda companies supplier also manufactures approvable letters indicated fda prepared approve ndas upon satisfaction certain specified conditions included resolution gmp compliance issues supplier supplier unable resolve gmp compliance issues may also receive approvable letter require resolution compliance issues condition obtaining marketing approval product compliance issues resolved timely manner able obtain fda approval manufacture aztreonam lysine inhalation facilities san dimas timely manner aztreonam lysine inhalation may approved anticipated timeframe anticipated sales drug may negatively impacted problems single suppliers depend may negatively impact development commercialization efforts depend relationships companies sales marketing performance revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada japan tobacco inc viread truvada emtriva japan gsk hepsera outside united states astellas pharma inc ambisome united states canada dainippon sumitomo pharma co ltd ambisome japan pfizer vistide roche tamiflu osi pharmaceuticals inc pfizer macugen many countries rely international distributors sales truvada viread emtriva hepsera ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including inability control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors table contents corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea success hepsera territories depend almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsks net sales hepsera well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera territories may substantially reduced addition letairis distributed thirdparty specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support letairis devote resources necessary sell letairis volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients thirdparty specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business dependent supplier inhalation device delivers aztreonam lysine inhalation regulatory approval obtained distribute device specialty pharmacies distribution channels control many key aspects related device example supplier could encounter issues regulatory agencies related device unable supply sufficient quantities device time commercial launch following launch issues may cause delay commercial launch aztreonam lysine inhalation would able realize anticipated contribution aztreonam lysine inhalation financial results table contents expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs may cause operating results fluctuate quarter quarter sales fluctuations result inventory levels held wholesalers parallel importation make difficult us accurately forecast sales may cause earnings fluctuate could adversely affect stock price estimate future demand products consider shelf life inventory regularly review realizability inventory actual demand less estimated demand could required record inventory writedowns would adverse impact results operations example result review inventory realizability first fourth quarters recorded writedowns portion gilead access program inventory year ended december approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand us wholesalers entered inventory management agreements may completely effective matching inventory levels end user demand make estimates determine end user demand nonretail sector united states includes government institutions including state aids drug assistance programs correctional facilities large health maintenance organizations contributed approximately sales hiv products united states december tends less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror purchasing patterns seen retail sector european union required permit products purchased one country sold another country allows buyers countries governmentapproved prices products relatively high purchase products countries prices products relatively low purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers us cause relative sales levels various countries fluctuate quarter quarter difficult forecast addition wholesalers may attempt arbitrage pricing differential countries purchasing excessive quantities products activities may result fluctuating quarterly sales certain countries reflect actual demand products customers quarterly fluctuations may impact earnings could adversely affect stock price example experienced increased sales hiv products france believe portion products reexported countries resold higher prices sales truvada viread france countries sales reexported may continue fluctuate activities continue france european countries elsewhere results operations could adversely affected success depend significant degree ability protect patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights table contents preserve trade secrets operate without infringing proprietary rights others properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential least period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents addition competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful addition time time certain individuals entities may challenge patents example march public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient truvada atripla viread pto granted requests july pto issued nonfinal rejections four patents step common reexamination proceeding initiate reexamination process predict ultimate outcome office actions unsuccessful responding office actions original claims patents may narrowed invalidated pto narrows invalidates patents may cause similar organizations seek examination proceedings challenging patents foreign jurisdictions patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b infection indication hepsera developed flolans patent market exclusivity protection expired result one generic pharmaceutical companies may launch generic version flolan united states may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated nda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully august pto adopted new rules scheduled become effective november october gsk successfully obtained preliminary injunction implementation table contents rules rules include limitations number claims permitted patent application number continuing patent applications filed rules implemented may limited ability obtain broad patent coverage products product candidates may allow competitors market products similar obtain patent coverage closely related products success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation leap restricted distribution program designed support letairis evaluating patents relevance leap addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors significant portion product sales occur outside united states currency fluctuations may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro use foreign currency forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business net foreign currency exchange impact pretax earnings including revenues expenses generated outside united states impact hedging activities favorable million compared hedging program hedges portion total exposure significant foreign exchange rate fluctuations within short period time could adversely affect results operations face credit risks european customers may adversely affect results operations european product sales governmentowned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices accounts receivable governmentowned supported customers countries totaled approximately million december historically receivables accumulated period time settled large lump sum payments government funding became available significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected table contents product revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hivinfected patients developing countries august agreement revenues would adversely affected addition established partnerships ten indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter year ended december observed increase crossborder sales european union required permit crossborder sales us consumers able purchase products including hiv products internet pharmacies countries substantial discounts crossborder sales could adversely affect revenues gross margin countries may required grant compulsory licenses products face generic competition products number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread result discussions brazilian government reached agreement brazilian health ministry may reduce price viread brazil approximately addition concerns cost availability tamiflu related potential avian flu pandemic generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing leastdeveloped countries canadas access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales table contents existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales truvada atripla viread hepsera ambisome vistide letairis subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase pricing pressures united states internationally pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success truvada atripla viread emtriva hepsera ambisome tamiflu also depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization twelve months also expect success product candidates particularly europe depend ability obtain reimbursement product candidates commercialized even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase new drugs come market may face significant price decreases products across european countries believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth results operations could adversely affected current future health care reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited initially patients transitioning medicaid medicare part longer term impact new law business yet clear us impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category entities providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients results operations could materially adversely affected reimbursement changes emerging medicare prescription drug coverage legislation addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules additionally health care reform federal state levels could adversely affect payment drugs time states already enacted health care reform legislation table contents may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability product liability insurance decreased cost defend lawsuits pay damages product liability claims may exceed coverage could impair financial condition ability clinically test product candidates market products addition claims regardless merit may impair financial condition future demand products assumptions used determine selfinsurance levels could wrong materially impact business continually evaluate levels selfinsurance based historical claims experience demographic factors severity factors actuarial assumptions however future occurrences claims differ assumptions historical trends results operations business cash flow financial condition could materially impacted claims expenses expensive litigation government investigations may reduce earnings along certain officers former officer named defendants class action lawsuit alleging violations federal securities laws lawsuit dismissed court however plaintiffs appealed dismissal november received subpoena us attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva complied us attorneys subpoena intend cooperate related government investigation outcome lawsuit lawsuits brought us investigation investigations brought us inherently uncertain adverse developments outcomes result significant monetary damages penalties injunctive relief us could significantly reduce earnings cash flows changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings finalization federal state foreign income tax audits impact income tax provision resulting abovementioned factors may significant could negative impact net income income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years franchise tax board california tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions adverse resolution one exposures reporting period could material impact results operations period changes accounting may affect financial position results operations us generally accepted accounting principles related implementation guidelines interpretations highly complex involve subjective judgments changes rules interpretation adoption new pronouncements application existing pronouncements changes business could significantly affect financial position results operations table contents example august fasb issued comment proposed financial accounting standards board fasb staff position fsp apb accounting convertible debt instruments may settled cash upon conversion including partial cash settlement fsp apb proposed fsp apb addresses instruments commonly referred instrument c eitf issue convertible bonds issuer option settle cash upon conversion requires issuer settle principal amount cash conversion spread cash net shares issuers option proposed fsp apb requires bifurcation conversion option debt instrument classification conversion option equity accretion resulting discount debt result additional interest expense reported income statement november expiration initial comment period fasb announced would begin redeliberations guidance proposed fsp january final guidance issued predict ultimate outcome including final guidance effective believe fasb determines account instrument c securities manner described accounting convertible senior notes would affected change presentation balance sheet adverse impact results operations would material fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties corporate headquarters including principal offices commercial administrative research development rd facilities located foster city california location buildings lease facilities san dimas california house manufacturing warehousing rd activities addition also lease facilities durham north carolina westminster colorado seattle washington house administrative rd activities european headquarters include commercial medical administrative facilities located london area united kingdom also lease facilities dublin area ireland house manufacturing distribution activities acquired manufacturing facility cork ireland september connection acquisition nycomed limited transferred certain operations dublin area site facility utilize site primarily solid dose tablet manufacturing antiviral products well product packaging activities also manufacturing facility edmonton alberta canada use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes table contents addition leased additional facilities house commercial medical administrative activities australia austria belgium canada france germany greece italy netherlands portugal spain sweden switzerland turkey united kingdom believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet longterm growth needs item legal proceedings information pertaining legal proceedings found heading legal proceedings item note commitments contingencies consolidated financial statements pages annual report incorporated reference herein item submission matters vote security holders matters submitted vote security holders quarter ended december table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq global select market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception currently expect retain earnings use operation expansion business therefore anticipate paying cash dividends near future table contents performance graph following graph compares total stockholder returns past five years four indices standard poors stock index labeled sp index nasdaq biotechnology index labeled nasdaq biotechnology index nasdaq crsp total return index nasdaq global select market us companies labeled nasdaq us index nasdaq pharmaceutical index labeled nasdaq pharmaceutical index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nasdaq biotechnology index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nasdaq biotechnology index relevant comparator since composed peer companies linesof business similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nasdaq biotechnology sp nasdaq us nasdaq pharmaceutical indices december table contents issuer purchases equity securities october board directors authorized program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated share repurchase transactions similar arrangements stock repurchase program expires december table summarizes stock repurchase activity three months ended december thousands except per share amounts maximum total number fair value shares total number shares purchased may yet shares average price part publicly purchased purchased paid per share announced programs program october october november november december december total difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock award order satisfy applicable tax withholding obligations table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development total costs expenses income loss operations gain warrant provision benefit income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible debt retained earnings accumulated deficit otal stockholders equity completed acquisition nycomed limited aggregate purchase price million allocated primarily property plant equipment completed acquisition myogen inc aggregate purchase price billion billion allocated purchased inprocess research development iprd million allocated deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated table contents gilead sciences inc selected consolidated financial datacontinued goodwill million allocated net tangible assets also acquired net assets corus pharma inc million million allocated purchased iprd million allocated net deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated net tangible assets million allocated assembled workforce recognized million royalty revenue relating resolution dispute f hoffmannla roche ltd together hoffmannla roche inc roche also recorded tax provision benefit million related repatriation qualified foreign earnings american jobs creation act ajca recorded gain million related warrant purchase capital stock eyetech pharmaceuticals inc predecessor osi pharmaceuticals inc completed initial public offering completed acquisition net assets triangle pharmaceuticals inc aggregate purchase price million approximately million purchase price allocated purchased iprd also recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets adopted statement financial accounting standards revised sharebased payment modified prospective basis beginning january see notes consolidated financial statements september june implemented twoforone stock splits form stock dividend share per share amounts periods presented restated reflect stock splits issued billion principal amount convertible senior notes private placement entered uncollateralized million term loan agreement facilitate cash dividend distribution part repatriation qualified foreign earnings provisions ajca cash dividends declared paid common stock table contents item managements discussion analysis financial condition results operations following managements discussion analysis mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars executive summary past year marked th anniversary founding gilead achievement many important milestones continued discover develop commercialize innovative therapeutics areas unmet medical need grew product sales significantly executed several product approvals launches multiple territories inlicensed new compounds research pipeline well made progress product candidates already clinic integrated multiple sites acquired continued strengthen worldwide organization infrastructure operating results led product sales billion hiv product sales truvada atripla viread emtriva billion increased key driver total product sales growth compared total product sales truvada increased million compared prior year despite availability atripla united states since july atripla product sales increased million together truvada atripla sales comprised total product sales addition commercial progress success atripla united states partner bristolmyers squibb company bms expanded atripla collaboration include countries comprise european union well norway iceland december received approval european commission market sell atripla european territories already begun shipping atripla germany united kingdom austria expect launch product throughout remainder european union pricing sales marketing matters finalized approved atripla continues comprise larger proportion total product sales expect product gross margin continue decrease decrease results inclusion bmss sustiva efavirenz carries zero gross margin product sales cost goods atripla product gross margin decreased due higher percentage atripla mix product sales compared hepsera product sales increased driven primarily sales volume growth across major geographical regions well favorable foreign currency exchange environment ambisome product sales increased driven primarily sales volume growth europe well impact favorable foreign currency exchange environment due depreciation us dollar major european currencies foreign currency denominated product sales experienced net benefit foreign currency fluctuations considering impact hedging activities resulted foreign currency favorable impact approximately million pretax income compared addition growth product sales royalty revenues increased compared million royalty revenues recognized million recorded royalties sales tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche strong sales tamiflu roche including sales tamiflu related worldwide pandemic planning initiatives contributed increase royalty revenues despite higher royalties recognized roche recently announced expect see marked decline tamiflu sales related pandemic planning expect decline significantly reduce royalties receive sale tamiflu adversely impact financial results table contents june letairis ambrisentan product acquired acquisition myogen inc myogen approved us food drug administration fda treatment pulmonary arterial hypertension pah october filed supplemental new drug application nda fda well type ii variation european medicines evaluation agency emea marketing approval viread treatment chronic hepatitis b adults additionally november submitted nda fda marketing approval aztreonam lysine inhalation treatment pulmonary pseudomonas aeruginosa p aeruginosa infection people cystic fibrosis cf along regulatory filings made relation viread hepatitis b aztreonam lysine inhalation cf progressed development compounds drug candidates inlicensed collaboration partners including hiv area completed phase clinical trial elvitegravir gs novel integrase inhibitor hiv licensed japan tobacco inc integrase inhibitors represent new way attacking hiv potential treatment alternative patients developed resistance existing classes therapy pending positive outcome discussions fda emea concerning design phase program anticipate dosing patients phase clinical study elvitegravir hepatitis b area filed supplemental nda fda well type ii variation emea marketing approval viread treatment chronic hepatitis b adults applications based data obtained two key pivotal phase studies completed year anticipate decisions emea fda second third quarters respectively hepatitis c area presented preliminary data november lead compound hepatitis c virus gs nonnucleoside polymerase inhibitor investigating qt prolongations certain doses pending fdas consent plan reinitiate phase ab study gs define efficacy safety compound year also entered exclusive license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitors treatment fibrotic diseases caspase inhibitors showing potential treatments chronic hepatitis c diseases characterized tissue scarring fibrosis agreement granted us commercialization rights lglss investigational caspase inhibitors including gs evaluated ongoing phase clinical trial potential treatment chronic hepatitis c anticipate data end related collaboration paid million upfront license fee recorded research development rd expenses cardiovascular area plan continue enroll two phase clinical studies darusentan treatment resistant hypertension expect complete enrollment addition letairis pah approved united states june partner glaxosmithkline inc gsk rights ambrisentan territories outside united states received positive opinion european committee human medicinal products treatment pah february approved gsk market ambrisentan name volibris respiratory area presented data second two pivotal studies aztreonam lysine inhalation inhaled antibiotic treatment patients cf pulmonary infection p aeruginosa along nda filed fda november plan submit marketing authorization application emea second quarter also respiratory area completed phase study healthy volunteers gs proprietary formulation combination tobramycin fosfomycin inhalation begun enrolling patients two phase b clinical studies additionally august entered research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel inhibitors treatment pulmonary diseases connection collaboration paid million upfront license fee recorded rd expense made million investment parion table contents taken together programs contributed increase rd expenses compared expect research clinical activity areas continue increase rd expenses addition commercial clinical efforts continued expand worldwide organization infrastructure integrated sites acquired acquisitions corus pharma inc corus myogen raylo chemicals inc september acquired integrated nycomed limited cork ireland based manufacturing tableting operation transferred certain existing dublin operations nycomed facility cork utilize cork facility solid dose tablet manufacturing certain antiviral products product packaging activities part strategy better build manage expand presence new existing markets internationally established new subsidiaries turkey austria switzerland process establishing marketing subsidiaries belgium denmark finland netherlands norway sweden initiatives believe help reduce reliance thirdparty distributors also contributed increase selling general administrative sga expenses continue increase headcount expand marketing promotional activities countries continue see increase sga expenses continue expand internationally launch products new territories including atripla european territories strong operating results contributed operating cash flows billion helped fund rd activities corporate development opportunities worldwide infrastructure capital requirements well daily operating needs additionally strong cash position allowed us repurchase million common stock repurchases completed billion stock repurchase program initiated allowed us initiate billion stock repurchase program october addition entered amended restated credit agreement credit facility increased billion thereby providing greater access funds future requirements arise plan expand international footprint advance additional drug candidates clinic launch viread hepatitis b aztreonam lysine inhalation cf approved strengthening relationships corporate partners continues priority especially bms continue launch atripla european territories finally plan continue strengthen worldwide infrastructure better support growing employee customer base well better facilitate expanding manufacturing research development commercial activities critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts inventories prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various marketspecific assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements table contents revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management government rebates estimate amounts payable us governmentmanaged medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower price record allowances accounts receivable estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates million million million respectively representing total gross product sales respectively deducted gross product sales based current information available us actual government rebates claimed periods varied less estimates recorded periods december accrued government rebates million million respectively accrued liabilities allowance million million respectively recorded accounts receivable following table summarizes aggregate activity accrued government rebates allowance accrued liabilities accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total table contents allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations result increase allowance doubtful accounts inventories record writedowns value inventory based review bad batches experienced manufacturing process well quality control reviews inventory generally record inventory write downs relating estimated obsolescence risk competition primarily shelf life products long however current assumptions future production inventory levels demand competition change actual market conditions less favorable projected management additional inventory writedowns may required could negatively impact product gross margins results operations prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory university emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected future levels product sales incorporating emtricitabine present value future royalty obligation derived using weighted average cost capital review quarterly expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty potential indicators impairment include launch significant product competitor significant deviations recognized product sales compared forecast product safety issues recalls amortize prepaid royalties based effective royalty rate derive forecasted hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine would prospectively update royalty rate used amortize prepaid royalties may increase future royalty expense december prepaid royalty asset relating emtricitabine royalties paid emory million amortization expense relating prepaid royalty asset million million million years ended december respectively clinical trial accruals record accruals estimated clinical study costs clinical studies performed thirdparty contract research organizations cros costs significant component rd expenses incurred cro costs million million million respectively table contents accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment extensively outsource clinical trial activities usually perform small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management general costs typically total cro contract value actual basis percentage range significantly wider many contracts either expanded reduced scope compared original budget startup costs usually occur within months contract executed milestone eventdriven nature remaining activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed per unit prices vary length three months single dose phase study two years complex phase clinical study average length contracts upper end range order provide longterm safety efficacy data support commercial launches truvada viread atripla emtriva hepsera letairis material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance relating uncompleted services refunded contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated december differences actual estimated activity levels particular study material however management receive complete accurate information vendors underestimates activity levels associated study given point time would record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance would reduce valuation allowance period determination first made adjustment made determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted income tax benefit approximately million million respectively future effective income tax rate may affected factors changes tax laws regulations rates changing interpretation existing laws regulations impact accounting stockbased compensation changes international organization changes overall levels income tax june financial accounting standards board fasb issued fasb interpretation accounting uncertainty income taxes fin interpretation statement financial accounting table contents standards sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition january adopted fin increased liability unrecognized tax benefits million corresponding charge opening balance accumulated deficit permitted fin addition reclassified million unrecognized tax benefits shortterm income taxes payable noncurrent deferred tax assets longterm income taxes payable date adoption total federal state foreign unrecognized tax benefits million recorded primarily longterm income taxes payable consolidated balance sheet including accrued liabilities related interest million total unrecognized tax benefits january million recognized would reduced effective tax rate period recognition permitted provisions fin continue classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations december total federal state foreign unrecognized tax benefits million including interest million total unrecognized tax benefits million recognized would reduce effective tax rate period recognition respect unrecognized tax benefits currently unable make reasonably reliable estimate period cash settlement respective taxing authorities file federal state foreign income tax returns many jurisdictions united states abroad us federal california income tax purposes statute limitations remains open years inception due utilization net operating losses relating prior years income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years franchise tax board california tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions believe positions comply applicable laws periodically evaluate exposures associated tax filing positions record liabilities related uncertain tax positions based upon fin believe items currently pending material adverse effect consolidated financial statements although adverse resolution one items period could material impact results operations period prior adoption fin recorded liabilities related uncertain tax positions based upon sfas accounting contingencies stockbased compensation december fasb issued sfas revised sharebased payment sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values sfas r supersedes accounting principles board opinion accounting stock issued employees apb amends sfas statement cash flows january adopted sfas r using modified prospective method adoption permitted sfas r requires compensation expense recorded nonvested stock options stockbased awards beginning first quarter adoption accordance modified prospective method prior period amounts restated reflect provisions sfas r table contents prior adoption sfas r accordance provisions sfas elected follow apb fasb interpretation accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stockbased plans apb exercise price employee director stock options equal greater fair value underlying stock date grant compensation expense recognized however required sfas pro forma impact expensing fair value stock options employee stock purchase plan disclosed notes consolidated financial statements connection adoption sfas r refined valuation assumptions methodologies used derive assumptions however elected continue using blackscholes option valuation model fair value stock options granted prior adoption sfas r calculated using multiple option approach fair value stock options granted beginning january calculated using single option approach concurrent adoption sfas r determined blend historical volatility along implied volatility traded options stock would better measure market conditions expected volatility previously used historical stock price volatility reliable source volatility data estimate weightedaverage expected life stock options based historical cancellation exercise data related stock options well contractual term vesting terms awards record stockbased compensation expense using graded vesting expense attribution approach nonvested stock options granted prior adoption sfas r consistent expense attribution approach used historical sfas disclosures using straightline expense attribution approach stock options granted adoption sfas r currently believe straightline expense attribution approach better reflects level service provided vesting period awards stockbased compensation expense related stock options recognized net estimated forfeitures estimate forfeitures based historical experience result adoption sfas r recognize tax benefit stockbased compensation additional paidincapital apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements operations rather apic years ended december recognized stockbased compensation expense million million respectively operating expenses capitalized million million respectively inventory december unrecognized stockbased compensation million related nonvested stock options expect expense estimated weightedaverage period years management discussed development selection disclosure critical accounting policies audit committee board directors audit committee reviewed disclosure presented relating results operations total revenues total revenues billion billion billion included total revenues product sales royalty revenues contract revenues table contents product sales product sales last three years consisted following thousands change change hiv products truvada atripla viread emtriva total hiv products hepsera ambisome total product sales total product sales increased compared primarily due increase total product sales volume billion favorable foreign currency exchange impact million total product sales increased compared primarily due increase total product sales volume million significant percentage product sales continued denominated foreign currencies used forward option contracts hedge percentage forecasted international sales primarily denominated euro reduced eliminate fluctuations sales due changes foreign currency exchange rates hiv products hiv product sales increased compared compared primarily driven product sales volume growth average selling prices hiv products increased compared primarily driven higher overall selling prices hiv products well transition patients united states coverage medicaid medicare part generally reimbursed higher rates estimated benefit net product sales resulting transitions approximately million truvada truvada sales increased compared compared case primarily driven strong sales volume growth europe well favorable foreign currency exchange environment truvada sales accounted total hiv product sales respectively atripla atripla sales increased compared primarily due first full year atripla sales well continued strong uptake atripla united states consolidate atripla product sales primary beneficiary joint venture bms united states efavirenz portion atripla sales approximately million million respectively atripla approved sale united states july european union december atripla sales accounted total hiv product sales sales atripla european union significant viread viread sales decreased compared compared case primarily due lower sales volume united states europe driven impact table contents patients switching vireadcontaining regimen one containing truvada andor atripla countries truvada andor atripla available partially offset sales volume increases latin america well favorable foreign currency exchange environment viread sales decrease compared also partially offset favorable foreign currency exchange environment emtriva emtriva sales decreased compared compared decreases years primarily due overall sales volume decreases driven impact patients switching emtrivacontaining regimen one containing truvada andor atripla countries products available hepsera hepsera sales increased compared primarily driven sales volume growth across major geographical regions product sold well favorable foreign currency exchange environment hepsera sales increased compared primarily driven sales volume growth united states europe hepsera sales volume also increased respect sales hepsera gsk sell hepsera gsk manufacturing cost connection gsks distribution activities asia collect royalty gsk upon sale hepsera customers record royalty revenues ambisome sales ambisome increased compared primarily due sales volume growth europe well favorable foreign currency exchange impact sales ambisome increased one percent compared primarily due sales volume growth regions partially offset lower pricing regions ambisome product sales united states relate solely sales ambisome astellas pharma inc recorded manufacturing cost expect total product sales continue grow continue expand sales marketing efforts royalty revenues following table summarizes period period changes royalty revenues thousands change change royalty revenues significant source royalty revenues sales tamiflu roche royalty revenues million increase compared million increase compared increases comparative periods primarily driven recognition tamiflu royalties roche million million respectively increases tamiflu royalties comparative periods due higher tamiflu sales recorded roche including sales related pandemic planning initiatives worldwide increase tamiflu royalties compared also due elimination contractual cost goods adjustment resulting dispute resolution november historically reduced amount tamiflu royalties recognized us prior november recognize royalties tamiflu sales roche quarter following quarter sold table contents november resolved dispute roche relating development license agreement agreed terminate related arbitration pending roche us related dispute resolution roche paid us million recognized payment royalty revenue payment consisted million relating disputed royalties million relating reimbursement contractual cost goods adjustment previously reduced earned royalties million relating updating royalties payable us first nine months based thencurrent royalty rates instead prior years effective royalty rate roche reported january expects significant decrease tamiflu sales compared therefore expect royalty revenues significantly lower compared cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin compared primarily due product mix changes especially atripla lower product gross margin comprised larger proportion product sales product gross margin compared lower gross margin compared primarily due launch atripla united states million writedowns inventory gilead access program estimated net realizable value well product mix changes patients continued switch viread higher margin product truvada andor atripla lower gross margin compared partially offset lower effective royalty rate resulting july emtricitabine royalty buyout discussed lower active pharmaceutical ingredients costs higher average selling prices hiv products united states atripla product sales decreased product gross margin without corresponding impact product gross profit primary beneficiary joint venture bms united states consolidate atripla product sales benefit product gross margin truvada portion atripla efavirenz portion atripla product sales carries zero product gross profit gross margin since joint venture purchases efavirenz bms bmss average net selling price efavirenz united states prior july paid royalties emory worldwide net sales product containing emtricitabine july royalty pharma purchased respectively royalty interest owned emory exchange elimination royalty obligation result purchase capitalized million prepaid royalties representing share million purchase price third quarter began amortize prepaid royalty cost goods sold remaining life underlying patent based effective royalty rate derived forecasted sales products containing emtricitabine record royalties royalty pharma based actual emtricitabine net sales relative royalty pharmas ownership interest underlying emory royalty interest expect product gross margin lower compared primarily due higher mix atripla product sales include efavirenz portion atripla product sales zero product gross profit partially offset product gross margin improvements driven lower active pharmaceutical ingredients costs table contents research development expenses following table summarizes period period changes major components rd expenses last three years thousands change change research clinical development pharmaceutical development total research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed cros materials supplies licenses fees overhead allocations consisting various support facilities related costs rd activities separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development expenses consist costs product formulation chemical analysis rd expenses increased million compared primarily due increased compensation benefits expenses million due largely higher headcount increased clinical study expenses million increased contract service expenses million relating clinical product development research activities cardiovascular programs addition paid million upfront license fee lgls million license related fee pari gmbh pari expensed future alternative uses technologies rd expenses increased million compared primarily due increased compensation benefits expenses million due largely higher headcount included stockbased compensation expense million adoption sfas r january well increased contract service clinical study expenses million relating clinical product development research activities hiv hepatitis programs respiratory cardiovascular programs assumed acquisitions myogen corus higher expenses partially offset lower milestone payments made japan tobacco inc japan tobacco compared related licensing development elvitegravir lead integrase inhibitor candidate also known gs well million payment emory connection amendment license agreement emory related obligation develop emtricitabine hepatitis b indication general significant collaboration payments like made lgls pari japan tobacco emory cause rd expenses fluctuate period period expect rd expenses increase levels due increased spending internal collaborative rd efforts relating progress product candidates advanced clinical studies well continuation clinical trials related elvitegravir hiv darusentan resistant hypertension viread hbv initiation phase program letairis selling general administrative expenses following table summarizes period period changes sga expenses last three years thousands change change selling general administrative table contents sga expenses increased million compared increase primarily due increase compensation benefits expenses million due largely higher headcount well increase marketing promotional expenses million antiviral cardiovascular areas including related launch letairis treatment pah sga expenses increased million compared higher expenses primarily driven higher headcount increased compensation benefits million including stockbased compensation expense million adoption sfas r january increased expenses million contract services promotional programs relating business growth business development activities preparation launch atripla united states million writeoff certain capital assets related renovations corporate headquarter campus expect sga expenses increase primarily due higher costs incurred administrative activities sales marketing efforts support business growth well costs associated anticipated launches atripla european union viread hbv united states european union aztreonam lysine inhalation cf united states purchased inprocess research development expenses connection acquisitions myogen corus recorded purchased inprocess research development iprd expenses billion million respectively year ended december purchased iprd expense myogen represented estimated fair value myogens incomplete rd programs yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition summary programs acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trials completed prior acquisition date filed receptor antagonist era treatment pah nda fda december june fda approved letairis ambrisentan treatment pah united states additionally march emea validated marketing authorization application ambrisentan treatment pah filed collaboration partner gsk february ambrisentan received positive opinion european committee human medicinal products treatment pah marketed name volibris gsk upon approval darusentan orally active etaselective era treatment resistant phase clinical development acquisition date date hypertension filing table contents estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return myogens operations comparable estimated weighted average cost capital companies myogens profile represents rate market participants would use value purchased iprd compensated differing phases development ambrisentan darusentan probabilityadjusting estimation expected future cash flows associated program determined time present value expected future cash flows using discount rate projected cash flows ambrisentan darusentan programs based key assumptions estimates revenues operating profits related programs considering stages development time resources needed complete development approval related product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets purpose estimating fair value ambrisentan program estimated program approximately complete acquisition date based estimated time cost complete phase clinical trials completed acquisition date estimated would incur future rd costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin ambrisentan assuming necessary regulatory approvals would received product would successfully commercialized date purpose estimating fair value darusentan program estimated program approximately complete acquisition date based estimated time cost complete remaining efforts would include completion phase clinical development well preparing filing nda fda acquisition date estimated would incur future rd costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin darusentan assuming necessary regulatory approvals would received product would successfully commercialized date remaining efforts completing darusentan iprd program primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain darusentan treatment resistant hypertension approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections darusentan may never successfully commercialized result may make strategic decision discontinue development darusentan example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results table contents purchased iprd expense corus represented estimated fair value coruss incomplete inhaled aztreonam lysine cf rd program yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition description program acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions inhaled aztreonam lysine cf aztreonam formulation inhalation used gram phase clinical trials acquisition date filed nda fda negative bacteria cause lung infections patients cf november granted target review date september estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return coruss operations comparable estimated weighted average cost capital companies coruss profile represents rate market participants would use value purchased iprd projected cash flows aztreonam lysine inhalation program based key assumptions estimates revenues operating profits related program considering stage development time resources needed complete development approval related product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets coruss two early stage candidates included valuation purchased iprd earlystage projects identifiable revenues expenses associated purpose estimating fair value aztreonam program estimated program approximately complete acquisition date based estimated time cost complete remaining efforts would include completion phase clinical development well preparing filing nda fda acquisition date estimated would incur future rd costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin aztreonam program assuming necessary regulatory approvals would received product would successfully commercialized date remaining efforts completing coruss iprd program primarily consist obtaining necessary regulatory approvals failing obtain fda regulatory body approvals risk could prevent completion development feedback regulatory authorities might require modifications delays later stage clinical trials additional trials performed certain aztreonam lysine inhalation treatment cf approved united states countries outside united states whether marketing approvals significant limitations use aztreonam lysine inhalation may never successfully commercialized result may make strategic decision discontinue development aztreonam lysine inhalation example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results table contents interest income net recorded interest income net million million million respectively decrease compared primarily attributable lower average cash investment balances well writedown million million relating otherthantemporary impairment investment achillion pharmaceuticals inc assetbacked commercial paper structured investment vehicle respectively increase compared primarily attributable higher average cash investment balances interest expense april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes collectively notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual terms notes incurred interest expense million million million respectively decrease interest expense compared primarily attributable repayment first quarter remaining amounts due term loan entered december increase interest expense compared primarily due interest term loan interest notes minority interest minority interest consolidated financial statements primarily reflects bmss interest operating results joint venture bms united states joint venture formed develop commercialize atripla united states primary beneficiary joint venture determined fasb interpretation r amended consolidation variable interest entities consolidate operations joint venture consolidated financial statements provision income taxes provision income taxes million million million respectively effective tax rate differs us federal statutory rate due primarily state taxes offset tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states included operating income pretax charges million billion iprd expenses associated corus myogen acquisitions respectively record income tax benefit related purchased iprd expenses amounts nondeductible effective tax rate differs us federal statutory rate due primarily federal tax nondeductible purchased iprd expenses state taxes offset tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states effective tax rate differs us federal statutory rate due generally state taxes offset recognition previously unbenefitted net operating loss tax credit carryforwards certain operating earnings nonus subsidiaries considered indefinitely invested outside united states onetime benefit qualifying dividends american jobs creation act ajca october ajca signed law ajca allowed deduction certain qualified foreign earnings repatriated defined ajca elected apply provision qualifying earnings repatriated earnings repatriation resulted onetime tax provision benefit approximately million recognized table contents june fasb issued fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition fin effective fiscal years beginning december january adopted fin increased liability unrecognized tax benefits million corresponding charge opening balance accumulated deficit permitted fin addition reclassified million unrecognized tax benefits shortterm income taxes payable noncurrent deferred tax assets longterm income taxes payable date adoption total federal state foreign unrecognized tax benefits million recorded primarily longterm income taxes payable consolidated balance sheet including accrued liabilities related interest million total unrecognized tax benefits million recognized would reduced effective tax rate period recognition permitted provisions fin continue classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations december total federal state foreign unrecognized tax benefits million including interest million total unrecognized tax benefits million recognized would reduce effective tax rate period recognition respect unrecognized tax benefits currently unable make reasonably reliable estimate period cash settlement respective taxing authorities liquidity capital resources following table summarizes cash cash equivalents marketable securities working capital cash flow activity end last three years thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase billion december increase billion primarily attributable net cash provided operations billion proceeds issuance stock employee stock plans million increases partially offset repurchase million common stock stock repurchase programs repayment remaining amounts due term loan million capital expenditures million relating expansion facilities accommodate growth table contents cash cash equivalents marketable securities totaled billion december decrease december decrease million primarily due net cash paid billion acquisitions myogen raylo corus million paid toward principal outstanding term loan entered decreases partially offset net cash provided operations billion net proceeds million issuance notes related transactions proceeds issuance stock employee stock plans million working capital working capital december billion compared billion december significant factors resulted increase working capital million increase cash cash equivalents shortterm marketable securities due primarily cash provided operating activities proceeds issuances stock employee stock plans partially offset repurchase common stock repayment term loan capital spending million increase prepaid taxes related intercompany profits gilead joint venture million increase accounts receivable primarily due increased sales working capital december billion compared billion december significant factors resulted decrease working capital billion decrease cash cash equivalents shortterm marketable securities primarily due funding significant acquisition activities well decrease marketable securities portfolio decrease resulting classification certain marketable securities longterm securities million increase accounts payable primarily due launch atripla july related purchases efavirenz bms bmss approximate market value efavirenz order joint venture build inventory levels supply increasing atripla demand working capital decreases partially offset million increase inventories primarily due increase atripla inventory included efavirenz purchased bms bmss approximate market value efavirenz million increase accounts receivable primarily due increased sales lower collections receivables certain european countries collections traditionally slower cash provided operating activities cash provided operating activities billion comprised primarily billion net income adjusted noncash items million stockbased compensation expense million deferred income taxes million tax benefits related employee stock plans million excess tax benefits stock option exercises partially offset million net cash outflow related changes operating assets liabilities table contents cash provided operating activities billion comprised primarily billion net loss adjusted noncash items billion purchased iprd expense stockbased compensation expense million million tax benefits related employee stock plans million excess tax benefits stock option exercises partially offset million net cash outflow related changes operating assets liabilities cash provided operating activities million comprised primarily million net income adjusted noncash items million tax benefits employee stock plans partially offset million net cash outflow related changes operating assets liabilities included million prepaid royalties made emory related emtricitabine cash used investing activities cash used investing activities primarily related purchases sales maturities availableforsale securities capital expenditures acquisition nycomed limited cash used investing activities primarily related purchases sales maturities availableforsale securities acquisitions myogen raylo chemicals inc raylo corus well capital expenditures cash used investing activities primarily related purchases sales maturities availableforsale securities used billion cash investing activities compared billion decrease million decrease primarily due acquisitions myogen raylo corus total billion well cash used purchases sales maturities marketable securities activities compared used billion cash investing activities compared million increase billion increase primarily due acquisitions myogen raylo corus total billion discussed well cash provided purchases sales maturities marketable securities activities compared capital expenditures made related primarily expansion manufacturing capabilities upgrades facilities well spending computer laboratory equipment accommodate business growth capital expenditures also included construction new building foster city california headquarters capital expenditures also included purchase two buildings previously leased well construction costs new building foster city california headquarters december capital expenditure commitments million expect fulfill commitments funds generated operating cash flows cash provided used financing activities cash used financing activities million primarily resulting million used repurchase common stock stock repurchase programs million used pay remaining amounts due term loan partially offset proceeds issuance stock employee stock plans million well million excess tax benefits stock option exercises cash provided financing activities million primarily resulting million net proceeds generated issuance notes related transactions addition received proceeds issuance stock employee stock plans million well million excess tax benefits employee stock option exercises cash inflows partially offset million paid towards principal term loan cash provided financing activities primarily related proceeds million term loan proceeds issuance stock employee stock plans million table contents information december along whollyowned subsidiary gilead biopharmaceutics ireland corporation gbic entered amended restated credit agreement superseded existing revolving credit agreement syndicate banks increase credit facility billion amended restated credit agreement also includes subfacility swingline loans letters credit terms amended restated credit agreement may borrow initially aggregate billion revolving credit loans loans amended restated credit agreement bear interest either libor plus margin ranging basis points basis points ii base rate defined amended restated credit agreement prepay outstanding borrowings time whole part without penalty premium outstanding interest principal would due payable december connection amended restated credit agreement entered parent guaranty agreement guaranteed obligations gbic amended restated credit agreement expect use proceeds loans amended restated credit agreement working capital requirements general corporate purposes december million letter credit outstanding amended restated credit agreement august result review terms existing corporate aircraft leases upon consideration various alternatives available us upon expiration entered agreements purchase three aircraft constructed delivery aggregate purchase price purchase agreements million december made deposits totaling million recorded noncurrent assets consolidated balance sheet future deposits due terms purchase agreements follows million million million million million million option terminate purchase agreements subject maximum payment fullyequipped price aircraft believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required assure available us favorable terms offbalance sheet arrangements offbalance sheet arrangements currently material reasonably likely material consolidated financial position results operations table contents contractual obligations contractual obligations consist debt obligations capital operating leases well purchase obligations primarily form capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact cancelable december thousands payments due period less one contractual obligations total year years years years convertible senior notes capital lease obligations operating lease obligations capital commitments purchase obligations clinical trials total december outstanding principal billion notes issued april december firm capital project commitments approximately million primarily relating expansion certain aspects manufacturing capabilities upgrading facilities december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated activities amounts related active pharmaceutical ingredients represent minimum purchase requirements actual purchases expected significantly exceed amounts december several clinical studies various clinical trial phases significant clinical trial expenditures cros although contracts cros cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications termination existing contracts anticipated potential new contracts addition committed make potential future milestone payments third parties part licensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheet included table respect total gross unrecognized tax benefit liabilities million december unable make reasonably reliable estimate period cash settlement respective taxing authorities amounts included longterm income taxes payable consolidated balance sheet included table recent accounting pronouncements december fasb issued sfas revised business combinations sfas r sfas r establishes principles requirements recognizing measuring assets acquired liabilities assumed noncontrolling interest acquiree business combination sfas r also provides guidance recognizing measuring goodwill acquired business combination requires acquirer disclose information needs evaluate understand financial effect business combination sfas r effective business combination transactions acquisition date december know whether sfas r material impact prospective consolidated financial statements table contents december fasb issued sfas noncontrolling interest consolidated financial statements amendment accounting research bulletin consolidated financial statements sfas sfas establishes accounting reporting standards ownership interests subsidiaries held parties parent amount consolidated net income loss attributable parent noncontrolling interest changes parents ownership interest valuation retained noncontrolling equity investments subsidiary deconsolidated sfas also establishes reporting requirements identify distinguish interest parent interest noncontrolling owners sfas effective fiscal years beginning december currently evaluating effect adoption sfas consolidated financial statements item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business significant percentage product sales denominated foreign currencies enter foreign exchange forward contracts foreign exchange option contracts partially mitigate impact changes currency exchange rates cash flows sales denominated foreign currencies also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected general market risks contracts offset corresponding gains losses transactions hedged recent years foreign currency exchange fluctuations primarily positive impact product sales gross margin however full impact foreign currency fluctuations moderated hedge program table contents following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward option contracts december contracts maturities months less average rates stated terms amount us dollars per foreign currency fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands foreign exchange forward contracts notional weighted average currency amount settlement price fair value british pound euro australian dollar total foreign exchange option contracts notional weighted average currency amount strike price fair value british pound euro australian dollar total total foreign exchange forward option contracts total notional amount billion total fair value relating liabilities million open foreign exchange forward option contracts december compares total notional amount billion total fair value relating liabilities million open foreign exchange forward contracts december interest rate risk portfolio availableforsale marketable securities fixed variablerate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december dollars thousands years ending december total fair value december thereafter assets availableforsale debt securities average interest rate liabilities convertible senior notes average interest rate capital lease obligations including current portion verage interest rate april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively may converted subject certain circumstances credit risk february began observing failed auctions auction rate securities whose underlying assets comprised student loans december held approximately million auction rate securities within availableforsale longterm marketable securities million securities whose underlying assets comprised student loans auction rate securities comprised approximately total cash cash equivalents marketable securities december auction rate securities including subject failed auctions currently rated aaa consistent high quality rating required investment policy believe given cash marketable securities position expected operating cash flows well access funds credit facility able hold securities recovery auction market related securities may final maturity accounts receivable balance december million compared million december growth accounts receivable balances primarily due higher product sales hiv products united states europe certain countries payments typically slow primarily greece italy portugal spain aggregated accounts receivable balance significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase credit risk related certain customers sales customers countries tend relatively slowpaying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled million million days past due date experienced significant losses respect collection accounts receivable believe substantially accounts receivable balances collectible perform credit evaluations customers financial condition generally required collateral table contents item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined securities exchange sec rules controls procedures company designed ensure information required disclosed company reports files submits securities exchange act amended exchange act recorded processed summarized reported within time periods specified secs rules forms based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined exchange act rule af internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report effectiveness internal control financial reporting december report audit internal control financial reporting appears table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting stockholders proxy statement headings nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference section proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference section proxy statement headings nominees certain relationships related transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document agreement plan merger among registrant gryphon acquisition sub inc corus pharma inc rodney ferguson phd chairman behalf stockholder representative committee dated april stock purchase agreement among registrant degussa ag laporte nederland bv raylo chemicals inc dated june agreement plan merger among registrant mustang merger sub inc myogen inc dated october restated certificate incorporation registrant amended certificate amendment restated certificate incorporation registrant certificate designation series junior participating preferred stock registrant amendment certificate designation series junior participating preferred stock registrant amended restated bylaws registrant amended restated may reference made exhibit exhibit exhibit exhibit exhibit amended restated rights agreement registrant chasemellon shareholder services llc dated october first amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated october second amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated may table contents exhibit exhibit footnote number description document indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april registration rights agreement among registrant merrill lynch pierce fenner smith incorporated morgan stanley co incorporated banc america securities llc goldman sachs co inc dated april form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september form option agreements used stock option plan letter agreement registrant iocbrega dated september registrants employee stock purchase plan amended may registrants stock option plan related agreements amended restated april amended january amended january registrants nonemployee directors stock option plan including form option agreement thereunder amended january amended january amendment agreement registrant iocbrega dated october amendment agreement registrant iocbrega dated december development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september nexstar pharmaceuticals incs incentive stock plan adopted february amended settlement agreement registrant successor nexstar pharmaceuticals inc astellas pharma inc successor fujisawa usa inc liposome company inc dated august gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement gilead sciences limited glaxo group limited dated april triangle pharmaceuticals inc stock incentive plan exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may table contents exhibit exhibit footnote number description document settlement agreement registrant successor triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may settlement exclusive license agreement registrant successor triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august master clinical commercial supply agreement gilead sciences limited ltd registrant patheon inc dated january licensing agreement registrant osi pharmaceuticals inc successor eyetech pharmaceuticals inc dated march amended may december april amendment licensing agreement eyetech pharmaceuticals inc registrant dated may amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant dated december amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant dated august amendment dated may licensing agreement dated april glaxo group limited gilead sciences limited license agreement japan tobacco inc registrant dated march tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated july royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july form employee stock option agreement used equity incentive plan form nonemployee stock option agreement used equity incentive plan gilead sciences inc corporate bonus plan first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september restated amended toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh dated november amended restated agreement registrant successor vestar inc astellas pharma inc successor fujisawa usa inc dated june gilead sciences inc code section bonus plan confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na table contents exhibit exhibit footnote number description document confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring emtricitabine manufacturing supply agreement gilead sciences limited degussa ag dated june corus pharma inc stock plan form corus pharma inc stock plan stock option agreement form restricted award agreement used equity incentive plan sixth amendment agreement license agreement institute organic chemistry biochemistry academy sciences czech republic k u leuven research development registrant dated august amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september form performance share award agreement used equity incentive plan license agreement registrant successor myogen inc abbott laboratories dated june license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor myogen inc glaxo group limited dated march addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated may form restricted stock unit issuance agreement company credit agreement dated december among registrant gilead biopharmacentics ireland corporation lenders parties thereto bank america na administrative agent swing line lender lc issuer parent guaranty agreement dated december registrant base salaries named executive officers offer letter dated october registrant caroline dorsa gilead sciences inc equity incentive plan amended october gilead sciences inc deferred compensation plan amended restated effective january gilead sciences inc severance plan amended restated effective january commercialization agreement dated december gilead sciences limited bristolmyers squibb company form employee stock option agreement used equity incentive plan revised january table contents exhibit exhibit footnote number description document form nonemployee director option agreement used equity incentive plan initial grants revised january form nonemployee director option agreement used equity incentive plan annual grants revised january subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certification chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed july incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed november incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed june incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference table contents filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended june incorporated herein reference filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs current report form k filed september incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed february incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants registration statement form filed august incorporated herein reference filed exhibit myogen incs registration statement form amended originally filed august incorporated herein reference filed exhibit myogen incs quarterly report form q filed may incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference filed exhibit registrants current report form k first filed december incorporated herein reference filed exhibit registrants current report form k also filed december incorporated herein reference filed exhibit registrants current report form k filed february incorporated herein reference management contract compensatory plan arrangement certification accompanies relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date irrespective general incorporation language contained filing certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act amended table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility companys management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements gilead sciences inc changed method accounting stockbased compensation accordance guidance provided statement financial accounting standards r sharebased payment also audited accordance standards public company accounting oversight board united states gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets longterm marketable securities noncurrent assets total assets liabilities stockholders equity current liabilities accounts payable accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion longterm obligations total current liabilities longterm deferred revenues convertible senior notes longterm income taxes payable longterm obligations minority interest commitments contingencies stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss retained earnings accumulated deficit total stockholders equity total liabilities stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development total costs expenses income loss operations interest income net interest expense minority interest income loss provision income taxes provision income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statement stockholders equity thousands common stock accumulated retained additional deferred earnings total paidin comprehensive stock accumulated stockholders shares amount capital income loss compensation deficit equity balance december net income unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december net loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive loss issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans reversal deferred stock compensation compensatory stock transactions assumption stock options connection acquisitions purchase convertible note hedges sale warrants deferred tax assets convertible note hedges repurchases common stock balance december adoption fin accounting uncertainty income taxes net income unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions repurchases common stock balance december see accompanying notes table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided operating activities depreciation amortization purchased inprocess research development stockbased compensation expense excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues minority interest net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisitions net cash acquired purchases nonmarketable equity securities capital expenditures net cash used investing activities financing activities proceeds issuances common stock proceeds term loan net issuance costs proceeds issuance convertible senior notes net issuance costs proceeds sale warrants purchases convertible note hedges repurchases common stock repayments longterm debt obligations excess tax benefits stockbased compensation net cash provided used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities reclassification achillion equity investment noncurrent assets marketable securities upon achillions initial public offering see accompanying notes table contents gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california marketing operations north america europe australia date focused efforts bringing novel therapeutics treatment lifethreatening diseases market expanded research development commercial focus include respiratory cardiovascular diseases acquisition myogen inc myogen corus pharma inc corus currently market truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah vistide cidofovir injection treatment cytomegalovirus cmv infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmanla roche ltd together hoffmanla roche inc roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us manufacture macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi sells macugen treatment neovascular agerelated macular degeneration royalty paying collaborative agreement us basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristolmyers squibb company bms primary beneficiary determined financial accounting standards board fasb interpretation revised december consolidation variable interest entities fin r record minority interest consolidated financial statements reflect bmss interest joint ventures significant intercompany transactions eliminated consolidated financial statements also include results companies acquired us date acquisition june completed twoforone stock split form stock dividend stockholders record may accordingly share per share amounts periods presented consolidated financial statements notes thereto adjusted retroactively applicable reflect stock split significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including related revenue recognition allowance doubtful accounts inventories prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates table contents gilead sciences inc notes consolidated financial statementscontinued revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured upon recognition revenue product sales provisions made government rebates customer incentives cash discounts prompt payment certain distributor fees estimated future returns products may expire appropriate items deducted gross product sales government rebates estimate amounts payable us governmentmanaged medicaid programs well certain qualifying federal state foreign government programs based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractuallydetermined covenants maintenance agreedupon inventory levels distributor fees based contractuallydetermined fixed percentage sales product returns provide customers general right product return permit returns product damaged defective received customer case product sold unites states product expired accept product returns united states expired one year expiration estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue sales ambisome recognized month following month corresponding sales occur royalty revenues sales products generally recognized received generally quarter following quarter corresponding sales occur table contents gilead sciences inc notes consolidated financial statementscontinued contract revenues contract revenue research development rd recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue obligations development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets contract revenues include net revenue product distribution services recognized persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured accordance emerging issues task force eitf issue reporting revenue gross principal versus net agent record product distribution services revenue net supply price paid manufacturerlicensor distribution fees paid specialty pharmacies allowances product returns cash discounts government rebates contract revenues consolidated statements operations shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components rd expenses consist personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees overhead allocations consisting various administrative facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development costs consist expenses incurred connection product formulation chemical analysis charge rd costs including clinical study costs expense incurred consistent statement financial accounting standards sfas accounting research development costs clinical study costs significant component rd expenses clinical studies performed thirdparty cros accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro monitor levels performance significant contract including extent patient enrollment activities communications cros adjust estimates required quarterly basis expenses reflect actual effort expended cro material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expense incurred point termination table contents gilead sciences inc notes consolidated financial statementscontinued amounts paid advance related incomplete services refunded contract terminated contracts include additional termination payments become due payable terminate contract additional termination payments recorded contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million earnings loss per share basic earnings loss per share calculated based weightedaverage number shares common stock outstanding period diluted earnings loss per share calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options equivalents assumed exercise warrants relating convertible senior notes due notes convertible senior notes due notes collectively notes determined treasury stock method notes considered instrument c securities defined eitf issue convertible bonds issuer option settle cash upon conversion eitf therefore conversion spread relating notes included diluted earnings per share calculation potential dilutive shares common stock resulting assumed settlement conversion spread notes determined method set forth eitf method settlement conversion spread notes dilutive effect average share price common stock period exceeds notes notes respectively average share price common stock year ended december exceeded conversion prices notes average share price common stock year ended december exceed either respective conversion prices notes warrants purchase million million weightedaverage shares common stock outstanding years ended december respectively included computation diluted earnings loss per share warrants exercise prices greater average market price common stock periods therefore effect antidilutive stock options purchase approximately million million weightedaverage shares common stock outstanding years ended december respectively included computation diluted earnings loss per share options exercise prices greater average market price common stock period therefore effect antidilutive due net loss approximately million weightedaverage number outstanding stock options common stock equivalents included computation diluted net loss per share inclusion would antidilutive table contents gilead sciences inc notes consolidated financial statementscontinued following table reconciliation numerator denominator used calculation basic diluted earnings loss per share thousands year ended december numerator net income loss denominator weightedaverage shares common stock outstanding used calculation basic earnings loss per share effect dilutive securities stock options equivalents conversion spread related convertible senior notes weightedaverage shares common stock outstanding used calculation diluted earnings loss per share stockbased compensation prior accordance provisions sfas accounting stockbased compensation sfas amended sfas accounting stockbased compensationtransition disclosure elected follow accounting principles board opinion accounting stock issued employees apb fasb interpretation accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stockbased plans apb exercise price employee director stock options equal greater fair value underlying stock date grant compensation expense recognized consolidated statements operations january adopted provisions sfas revised sharebased payment sfas r requires sharebased payments employees directors including grants stock options recognized consolidated statements operations based fair values sfas r also requires benefit tax deductions excess recognized compensation cost reported consolidated statements cash flows financing cash flow rather operating cash flow applied modified prospective method one adoption methods permitted sfas r requires compensation expense recorded vesting nonvested stock options stockbased awards beginning first quarter adoption sfas r accordance modified prospective method prior period amounts restated reflect adoption sfas r addition calculated pool excess tax benefits available within additional paidin capital apic accordance provisions sfas r cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least table contents gilead sciences inc notes consolidated financial statementscontinued fair value securities sold us eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position well severity duration unrealized losses determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review investments indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe certain countries payments typically slow primarily greece italy portugal spain aggregated accounts receivable balances significant cases slow payment practices countries reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled million million days past due december past due accounts receivable countries totaled million million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheets collectible perform credit evaluations customers financial condition generally required collateral table contents gilead sciences inc notes consolidated financial statementscontinued certain raw materials utilize operations obtained single suppliers many raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship products supply drug candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks government rebates cash discounts prompt payment doubtful accounts sales returns estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual obligations historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventory order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized prepaid royalties prepaid royalties capitalized cost initially equivalent present value future royalty obligation would expect pay licensor expected levels product sales incorporating related technology review quarterly expected future sales levels products indicators might require writedown net recoverable value change estimated life prepaid royalty amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term table contents gilead sciences inc notes consolidated financial statementscontinued office computer equipment includes capitalized software capitalized software purchased internally developed software december unamortized capitalized software costs million consolidated balance sheet amortized million capitalized software costs leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest million million capitalized respectively significant interest capitalized goodwill intangible assets goodwill represents excess purchase price estimated fair value net assets acquired business combination accordance sfas goodwill intangible assets sfas goodwill amortized required tested annually impairment test goodwill impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount accordance sfas intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset asset group impairment loss measured excess carrying value asset asset group estimated fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income loss accumulated separate component stockholders equity net foreign exchange transaction gains losses included interest income net consolidated statements operations net transaction gains totaled million million million respectively table contents gilead sciences inc notes consolidated financial statementscontinued hedge certain foreign currency exposures related outstanding trade accounts receivable forecasted product sales foreign exchange forward contracts foreign exchange option contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time limit risk counterparties contracts may unable perform transacting major banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions hedge net investment foreign subsidiaries fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets foreign exchange forward option contracts accounts payable longterm debt longterm obligations cash cash equivalents marketable securities see note foreign exchange contracts hedge accounts receivable see note reported respective fair values balance sheet foreign exchange contracts hedge forecasted sales recorded fair value net related deferred gain loss resulting reported net balance zero remaining financial instruments reported consolidated balance sheets amounts approximate current fair values income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects future effective income tax rate factors include limited interpretations existing tax laws changes tax laws rates accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings finalization federal state foreign income tax audits impact income tax provision resulting abovementioned factors may significant could negative impact net income january adopted fasb interpretation accounting uncertainty income taxes fin interpretation sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition result adoption fin increased liability unrecognized tax benefits million corresponding charge opening balance accumulated deficit permitted fin addition reclassified million unrecognized tax benefits shortterm income taxes payable noncurrent deferred tax assets longterm income taxes payable date adoption total federal state foreign unrecognized tax benefits million recorded primarily longterm income table contents gilead sciences inc notes consolidated financial statementscontinued taxes payable consolidated balance sheet including accrued liabilities related interest million total unrecognized tax benefits million recognized would reduced effective tax rate period recognition permitted provisions fin continue classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations recent accounting pronouncements december fasb issued sfas revised business combinations sfas r sfas r establishes principles requirements recognizing measuring assets acquired liabilities assumed noncontrolling interest acquiree business combination sfas r also provides guidance recognizing measuring goodwill acquired business combination requires acquirer disclose information needs evaluate understand financial effect business combination sfas r effective business combination transactions acquisition date december know whether sfas r material impact prospective consolidated financial statements december fasb issued sfas noncontrolling interest consolidated financial statements amendment accounting research bulletin consolidated financial statements sfas sfas establishes accounting reporting standards ownership interests subsidiaries held parties parent amount consolidated net income loss attributable parent noncontrolling interest changes parents ownership interest valuation retained noncontrolling equity investments subsidiary deconsolidated sfas also establishes additional reporting requirements identify distinguish interest parent interest noncontrolling owners sfas effective fiscal years beginning december currently evaluating effect adoption sfas consolidated financial statements derivative financial instruments derivatives recognized either assets liabilities measured fair value based quoted market prices enter foreign currency forward option contracts hedge changes fair value certain monetary assets liabilities denominated nonfunctional currency record changes fair value instruments interest income net derivative instruments designated hedges sfas nos accounting derivative instruments hedging activities collectively referred sfas enter foreign currency forward option contracts maturities months less hedge percentage future cash flows related forecasted product sales foreign currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified hedges related forecasted foreign currency product sales designated documented inception respective hedge designated cash flow hedges sfas evaluated effectiveness quarterly inception hedging relationship quarterly basis perform regression analysis using change cash flow underlying contract regressing change cash flow hedge instrument excluding time value assess effectiveness hedging relationship assess hedge effectiveness retrospective basis using dollaroffset approach monthly exclude time value effectiveness testing recognize changes time value hedge interest income net excluded gains million million million assessment hedge effectiveness respectively effective component hedge recorded table contents gilead sciences inc notes consolidated financial statementscontinued accumulated comprehensive income loss unrealized gain loss hedging instrument see note hedged forecasted transactions occur hedges dedesignated unrealized gains losses reclassified earnings time substantially values reported accumulated comprehensive income loss december reclassified earnings within months december net unrealized losses million million respectively open foreign exchange contracts gains losses cash flow hedges recorded product sales increased decreased product sales million million million respectively residual changes fair value instruments including resulting cancellation dedesignation hedge contracts ineffectiveness recognized immediately interest income net impact hedge ineffectiveness significant consolidated statements operations notional amounts foreign exchange forward option contracts outstanding billion december billion december liability fair value million million december respectively acquisitions nycomed limited september completed acquisition nycomed limited nycomed whollyowned irish subsidiary germanybased pharmaceutical company nycomed gmbh nycomed facility located cork ireland conducted manufacturing tableting operations nycomed gmbh transferred certain operations dublin ireland area site facility utilize site primarily solid dose tablet manufacturing existing future products well product packaging activities nycomed acquisition accounted business combination accordance sfas business combinations sfas results operations nycomed since completion acquisition september included consolidated statement operations aggregate purchase price nycomeds common stock million consisted cash paid closing million estimated direct transaction costs million employeerelated severance costs million employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction accordance eitf issue recognition liabilities connection purchase business combination eitf purchase price allocated primarily property plant equipment million remaining balance allocated net working capital september consider nycomed acquisition material business combination sfas therefore disclosed pro forma results operations required sfas material business combinations connection transfer certain operations dublin ireland area site cork facility finalized personnel plan respect dublin employees met criteria recognizing onetime termination benefits sfas accounting costs associated exit disposal activities fourth quarter estimated termination benefits totaled approximately million december also providing relocation retention benefits totaling approximately million million respectively employees targeted relocation cork facility retained provide service us certain period time table contents gilead sciences inc notes consolidated financial statementscontinued myogen inc november completed acquisition outstanding shares common stock myogen via cash tender offer terms agreement plan merger entered october myogen publiclyheld biopharmaceutical company based westminster colorado focused discovery development commercialization small molecule therapeutics treatment cardiovascular disorders myogen two product candidates latestage clinical development ambrisentan treatment patients pulmonary arterial hypertension pah darusentan treatment patients resistant hypertension acquisition provided us opportunity expand cardiovascular therapeutic area myogen acquisition accounted business combination accordance sfas results operations myogen since november included consolidated statements operations aggregate purchase price myogens common stock billion consisted cash paid prior closing billion fair value vested stock options assumed million direct transaction costs million consisted primarily investment banking fees employeerelated severance costs million reduction income taxes payable million resulted primarily exercise stock options assumed myogen vested acquisition date reduction income taxes payable resulted decrease aggregate purchase price employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction accordance eitf accordance merger agreement entered myogen conversion value stock option assumed determined based exercise price option purchase shares common stock myogen average closing price common stock five consecutive trading days immediately preceding including tender offer acceptance date november per share estimated fair value stock options assumed determined using average price per share approximated price would resulted averaging closing price common stock two trading days two trading days acceptance date accordance eitf issue determination measurement date market price acquirer securities issued purchase business combination fair value stock options assumed calculated using blackscholes valuation model following assumptions expected life ranging years riskfree interest rate ranging expected volatility ranging dividend yield fair value asconverted gilead stock options exceed fair value myogen stock options immediately prior exchange approximately million million asconverted shares subject outstanding myogen stock options fully vested acquisition date estimated fair value vested options million included purchase price estimated fair value unvested options million included purchase price recognized stockbased compensation expense remaining future vesting period options table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes purchase price allocation november thousands cash cash equivalents shortterm marketable securities accounts receivable net prepaid expenses assets accounts payable deferred revenue liabilities net tangible assets deferred tax assets purchased inprocess research development goodwill total purchase price million deferred revenue reflected fair value deferred revenue legal performance obligations accordance eitf issue accounting business combination deferred revenue acquiree million deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations concluded based standard set forth sfas likely realize benefits deferred tax assets elected treat myogen acquisition asset acquisition california state tax purposes purchased inprocess research development iprd goodwill resulting acquisition deductible california state income tax purposes although amounts deductible federal income tax purposes estimated fair value purchased iprd billion determined management purchased iprd represents myogens incomplete rd programs yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition within consolidated statement operations summary programs acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trials completed prior acquisition date filed nda fda receptor antagonist era treatment pah december june fda approved letairis ambrisentan treatment pah united states additionally march european medicines evaluation agency emea validated marketing authorization application ambrisentan treatment pah filed collaboration partner glaxosmithkline inc gsk february ambrisentan received positive opinion european committee human medicinal products treatment pah marketed name volibris gsk upon approval darusentan orally active etaselective era treatment resistant phase clinical development acquisition date currently still phase clinical hypertension development table contents gilead sciences inc notes consolidated financial statementscontinued estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return myogens operations comparable estimated weighted average cost capital companies myogens profile represents rate market participants would use value purchased iprd compensated differing phases development ambrisentan darusentan probabilityadjusting estimation expected future cash flows associated program determined time present value expected future cash flows using discount rate projected cash flows ambrisentan darusentan programs based key assumptions estimates revenues operating profits related programs considering stages development time resources needed complete development approval related product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets remaining efforts completing darusentan iprd program primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain darusentan treatment resistant hypertension approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections darusentan may never successfully commercialized result may make strategic decision discontinue development darusentan example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results excess purchase price fair value amounts assigned assets acquired liabilities assumed million represented goodwill amount resulting myogen acquisition recorded goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas goodwill tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount raylo chemicals inc november completed acquisition outstanding shares common stock raylo chemicals inc raylo whollyowned subsidiary germanybased specialty chemicals company degussa ag located edmonton canada raylos operations encompassed custom manufacturing active pharmaceutical ingredients advanced intermediates pharmaceutical biopharmaceutical industries utilize raylo site process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes table contents gilead sciences inc notes consolidated financial statementscontinued raylo acquisition accounted business combination accordance sfas results operations raylo since november included consolidated statements operations aggregate purchase price raylos common stock million consisted cash paid prior closing million direct transaction costs million employeerelated severance costs million employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction accordance eitf costs fully paid following table summarizes purchase price allocation november thousands net tangible assets gmp qualification intangible asset goodwill total purchase price million net tangible assets included million cash million property plant equipment million tangible assets less assumed liabilities million estimated fair value million associated good manufacturing practices gmp qualification raylos facilities determined management value recorded intangible asset amortized straightline basis three years estimated useful life asset determined management based amount time would derive benefit making substantial upgrades revisions acquired manufacturing practices december accumulated amortization asset million million respectively amortization expense recognized million million respectively estimated aggregate amortization expense recognized future years approximately million million excess purchase price fair value amounts assigned assets acquired liabilities assumed million represented goodwill amount resulting raylo acquisition recorded goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas goodwill tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount elected treat raylo acquisition asset acquisition federal california state tax purposes goodwill resulting acquisition deductible federal california state income tax purposes prior acquisition raylo one longstanding contract manufacturers determined accordance eitf issue accounting preexisting relationships parties business combination settlement preexisting relationship part business combination value needed assigned preexisting relationship purchase price allocation summarized raylos assets acquisition date included million trade receivables us eliminated consolidated balance sheet upon completion acquisition corus pharma inc august completed acquisition corus privatelyheld biopharmaceutical company based seattle washington corus development stage company focused development table contents gilead sciences inc notes consolidated financial statementscontinued commercialization novel drugs respiratory infectious diseases corus one lead product candidate latestage clinical trials two earlystage product candidates acquisition provided us opportunity expand respiratory therapeutic area well augment pipeline corus acquisition accounted acquisition assets rather business combination accordance criteria outlined eitf issue determining whether nonmonetary transaction involves receipt productive assets business sfas corus considered development stage company commenced planned principal operations additionally lacked necessary elements business including completed product therefore ability access customers results operations corus since august included consolidated statements operations april purchased million coruss series c preferred stock represented approximately coruss voting equity interests time conjunction purchase series c preferred stock also entered agreement plan merger option acquire merger remaining outstanding shares corus july announced agreed exercise option concurrently entered agreement novartis vaccines diagnostics inc novartis whereby novartis agreed dismiss litigation corus payment made us novartis since claims made novartis directly implicated coruss right develop commercialize products settling novartis deemed appropriate allow completion acquisition ensure claims novartis could impede ability develop commercialize coruss product candidates without settlement results ongoing trial time settlement would uncertain sustained period following closing due legal appeals potential proceedings upon completion acquisition included investment coruss series c preferred stock payment novartis part acquisition purchase price aggregate purchase price acquired shares million consisted cash paid prior closing million fair value vested stock options assumed million direct transaction costs million employeerelated severance costs million addition holdback amount million payable corus stockholders us one year closing merger except extent utilized pay claims made us within year assessed probable would pay holdback amount recorded amount accrued liabilities consolidated balance sheet acquisition date paid holdback amount million august employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction following table summarizes purchase price allocation august thousands net tangible assets assembled workforce net deferred tax assets purchased inprocess research development total purchase price million net tangible assets included million cash million investments million tangible assets less assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset million net deferred tax assets primarily related federal net operating loss tax credit table contents gilead sciences inc notes consolidated financial statementscontinued carryforwards certain state amortizations concluded based standard set forth sfas likely realize benefits deferred tax assets elected treat corus acquisition asset acquisition california state tax purposes purchased iprd resulting acquisition deductible california state income tax purposes although amount deductible federal income tax purposes estimated fair value purchased iprd assembled workforce determined management estimated fair value purchased iprd greater purchase price paid therefore amount allocated purchased iprd consisted net amount remaining allocating purchase price net tangible assets assembled workforce net deferred tax assets purchased iprd represented coruss incomplete rd program yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition within consolidated statement operations summary program acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions inhaled aztreonam lysine cystic fibrosis cf aztreonam formulation inhalation used gram phase clinical trials acquisition date filed nda fda negative bacteria cause lung infections patients cf november granted target review date september estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return coruss operations comparable estimated weighted average cost capital companies coruss profile represents rate market participants would use value purchased iprd projected cash flows aztreonam lysine inhalation program based key assumptions estimates revenues operating profits related program considering stage development time resources needed complete development approval related product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets coruss two early stage candidates included valuation purchased iprd earlystage projects identifiable revenues expenses associated remaining efforts completing coruss iprd program primarily consist obtaining necessary regulatory approvals failing obtain fda regulatory body approvals risk could prevent completion development feedback regulatory authorities might require modifications delays later stage clinical trials additional trials performed certain aztreonam lysine inhalation treatment cf approved united states countries outside united states whether marketing approvals significant limitations use aztreonam lysine inhalation may never successfully commercialized result may make strategic decision discontinue development aztreonam lysine inhalation example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given table contents gilead sciences inc notes consolidated financial statementscontinued underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results acquisition real estate august completed purchase two additional buildings located foster city california campus aggregate purchase price million purchase price allocated land buildings land improvements based estimated relative fair values determined management million million million respectively fair value buildings land improvements depreciated remaining useful lives asset disposal march received local city approval proceed demolition two buildings foster city california begin construction new facility included charge associated writeoff buildings equal aggregate net book value million sga expenses availableforsale securities following summary availableforsale securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december debt securities us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total debt securities equity securities total december debt securities us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total debt securities equity securities total table contents gilead sciences inc notes consolidated financial statementscontinued december debt securities consisted primarily money market funds auction rate securities following table presents classification availableforsale securities consolidated balance sheets thousands december cash cash equivalents shortterm marketable securities longterm marketable securities total december portfolio availableforsale debt securities comprised million securities contractual maturity less one year billion securities contractual maturity greater one year less five years million securities contractual maturity greater five years less ten years million securities contractual maturity greater ten years securities contractual maturity greater ten years comprised assetbacked securities included mortgagebacked securities auctionrate securities following table presents certain information related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales december following availableforsale debt securities continuous unrealized loss position deemed otherthantemporarily impaired thousands less months months greater gross gross unrealized estimated unrealized estimated losses fair value losses fair value december us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities total december us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities total table contents gilead sciences inc notes consolidated financial statementscontinued december gross unrealized losses caused increase yieldtomaturity underlying securities approximately total number investment positions unrealized loss positions significant facts circumstances arisen indicate deterioration creditworthiness issuers securities based review securities including assessment duration severity related unrealized losses ability intent hold investments maturity otherthantemporary impairments securities december result review investments otherthantemporary impairment december recorded charge million interest income net writedown cost basis investments common stock achillion pharmaceuticals inc achillion assetbacked commercial paper abcp structured investment vehicle million million respectively otherthantemporary impairment achillion based quoted market price achillion common stock last trading day december compared cost basis assessment based primarily observation quoted market value investment less carrying value three consecutive quarters see note otherthantemporary impairment abcp based various market factors including estimated fair value underlying collateral abcp december investment common stock achillion abcp million million respectively recorded longterm marketable securities shortterm marketable securities respectively consolidated balance sheet european headquarters relocation june announced commercial medical administrative groups european headquarters based paris france would relocated london area united kingdom european headquarters regulatory safety information technology groups already located cambridge area united kingdom believed relocation would enable us achieve efficiencies closer proximity groups continue position company compete large pharmaceutical companies global level french subsidiary continues occupy paris facilities continue maintain expand sales marketing presence france third quarter relocation plans finalized accrued charge million primarily consisting employee severance costs termination benefits included sga expenses majority severance costs termination benefits paid thereby reducing relocation accrual included accrued compensation employee benefits consolidated balance sheets insignificant amount additional costs relating new headquarters united kingdom including recruitment costs legal expenses capital expenditures related costs expensed incurred significant relocation activities completed aggregate severance relocation recruiting costs resulting relocation european headquarters totaled approximately million table contents gilead sciences inc notes consolidated financial statementscontinued inventories inventories summarized follows thousands december raw materials work process finished goods total inventories december joint venture formed gilead bms included consolidated financial statements held million million inventory respectively efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz see note established gilead access program december pursuant make truvada viread available substantially reduced prices countries developing world based regular evaluation forecasted sales pricing inventory shelf life concluded would fully recover full carrying value associated inventory truvada viread gilead access program result recorded million year ended december cost goods sold writedown inventory estimated net realizable value consolidated balance sheet detail thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction inprogress subtotal less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total accrued liabilities accrued government rebates accrued royalties liabilities total table contents gilead sciences inc notes consolidated financial statementscontinued collaborative arrangements contracts result entering strategic collaborations time time may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure provisions fin r december determined certain investee companies variable interest entities however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america december entered collaboration bms develop commercialize single tablet regimen containing truvada bmss sustiva united states collaboration structured joint venture operates limited liability company consolidate named bristolmyers squibb gilead sciences llc ownership interests joint venture thus sharing product revenue costs reflect respective economic interests bms us based proportions net selling price atripla attributable sustiva truvada since net selling price truvada may change time relative net selling price sustiva bms respective economic interests joint venture may vary annually share marketing sales efforts bms parties obligated provide equivalent sales force efforts minimum number years responsible accounting financial reporting tax reporting product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values july joint venture received approval fda sell atripla united states september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada october joint venture received approval health canada sell atripla canada december joint venture held sustiva active pharmaceutical ingredient purchased bms bmss estimated net selling price sustiva us market amount included inventory consolidated balance sheet see note europe december gilead sciences limited gsl one whollyowned subsidiaries ireland bms entered collaboration arrangement commercialize distribute atripla european union norway iceland switzerland liechtenstein european territory parties formed trisupply limited trisupply limited liability company consolidate manufacture atripla distribution europe arrangement trisupply purchases efavirenz bmss estimated net selling price efavirenz european territory responsible product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling returns territories copromote atripla bms also responsible accounting financial reporting tax reporting collaboration december european commission approved atripla sale european union december trisupply held efavirenz purchased bms bmss estimated net selling price efavirenz european territory amount included inventory consolidated balance sheets see note parties formed bristolmyers squibb gilead sciences limited limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities table contents gilead sciences inc notes consolidated financial statementscontinued share marketing sales efforts bms major market countries parties agreed provide equivalent sales force efforts revenue cost sharing based relative ratio truvada efavirenzs respective net selling prices pari gmbh result acquisition corus august assumed rights february development agreement corus pari gmbh pari development aztreonam lysine inhalation development inhalation delivery device drug product terms agreement obligated pay pari services rendered subject achievement specific milestones obligated pay certain milestone payments pari addition make royalty payments based net sales aztreonam lysine inhalation approved commercialization agreement also provided us right reduce royalty rates payable pari november paid pari million reduce royalty rate agreement aztreonam lysine inhalation yet approved commercialization recorded payment rd expenses consolidated statement operations lg life sciences ltd november entered license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitors treatment fibrotic diseases agreement granted us commercialization rights lglss caspase inhibitors including lb known gs terms agreement license worldwide exception korea china india lgls retained rights lgls also retains right develop commercialize caspase inhibitors ophthalmic topical uses worldwide accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement operations future alternative use technology agreement also obligated us fund collaborative research program two years identify potential caspase inhibitor drug candidates addition obligated make additional milestone payments million upon achievement certain development regulatory commercial objectives also obligated pay royalties future net sales products developed approved relation collaboration parion sciences inc august entered research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel inhibitors treatment pulmonary diseases agreement granted us worldwide commercialization rights p gs epithelial sodium channel enac inhibitor discovered parion treatment pulmonary diseases including cf chronic obstructive pulmonary disease noncf bronchiectasis accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement operations future alternative use technology made million investment parion form convertible debt recorded noncurrent assets consolidated balance sheet collaboration agreement lead development commercialization activities provide funding full time equivalents certain research activities addition obligated make additional payments upon achievement certain milestones pay royalties future net sales products developed approved relation collaboration table contents gilead sciences inc notes consolidated financial statementscontinued roche september entered development license agreement agreement f hoffmannla roche ltd hoffmannla roche inc together roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs november entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement roche paid us million recognized royalty revenues consisting million relating disputed royalties million relating reimbursement cost goods adjustment million relating updating royalties payable us first nine months based thencurrent royalty rates instead prior years effective royalty rate recorded total million million million tamiflu royalties respectively emory university july royalty pharma purchased royalty interest owned emory university emory emtricitabine hiv indication terms agreement royalty pharma paid respectively total purchase price million emory exchange elimination emtricitabine royalties due emory worldwide net sales product containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million amortize prepaid royalty cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales million million million amortized cost goods sold respectively record royalties royalty pharma based actual emtricitabine net sales relative royalty pharmas ownership underlying emory royalty interest paid royalties million million million royalty pharma respectively table contents gilead sciences inc notes consolidated financial statementscontinued july made payment million emory connection amendment restatement existing license agreement emory providing us greater strategic flexibility development emtricitabine hepatitis b indication recorded payment rd expenses expecting significant related rd next several years prior july paid royalties emory respect emtricitabine hiv indication worldwide license acquired acquisition triangle pharmaceuticals inc triangle paid royalties million net sales emtricitabine institute organic chemistry biochemistry academy sciences czech republic rega stichting entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements received exclusive right manufacture use sell nucleotide compounds obligated pay iocbrega percentage net revenues received sales products containing patented compounds subject minimum royalty payments compounds covered original agreements include cidofovir active pharmaceutical ingredient vistide adefovir active pharmaceutical ingredient hepsera tenofovir active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla december agreements iocbrega amended provide reduced royalty rate future sales products containing tenofovir adefovir return upfront payment us million upon signing agreement payment recorded prepaid royalty classified assets consolidated balance sheets prepaid royalty amortized cost goods sold expected commercial life tenofovir adefovir amortization million payment began product launch dates viread hepsera december million remained amortized make quarterly payments iocbrega based percentage truvada atripla viread hepsera vistide net sales august iocbrega agreed waive right royalty sales truvada viread developing countries sell products substantially reduced prices gilead access program sales atripla distributed merck co inc developing countries paid royalties million million million iocbrega respectively japan tobacco inc july granted japan tobacco inc japan tobacco right commercializes viread truvada emtriva japan terms agreement received upfront license fee million received additional payments upon achievement certain milestones japan tobacco also pays us royalty net sales products japan upfront license fee recorded deferred revenue amortized contract revenue period supply products japan tobacco approximately ten years remaining december received million year milestone payments japan tobacco related japanese regulatory approval marketing authorization viread emtriva truvada amortizing remaining period upfront license fee table contents gilead sciences inc notes consolidated financial statementscontinued march japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor known gs countries world excluding japan japan tobacco retained rights terms agreement incurred upfront license fee million included rd expenses future alternative use technology march recorded million rd expenses related milestone incurred result dosing first patient phase clinical study obligated make additional payments upon achievement milestones well pay royalties based future product sales territories may market drug achillion pharmaceuticals inc november achillion granted us worldwide rights research development commercialization certain small molecule hepatitic c virus hcv replication inhibitors involving hcv protease treatment hepatitis c collaboration achillion obligated continue development inhibitor compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofofconcept shared equally achillion us following proofofconcept study obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration paid million upfront license fee recorded rd expenses future alternative use licensed technology additionally invested achillions convertible preferred stock agreed make payments achillion upon achievement certain milestones outlined agreement well pay royalties future net sales products arising collaboration october achillion completed initial public offering convertible preferred stock converted shares achillion common stock december achillion began dosing hcvinfected patients phase clinical study gs also known ach treatment hepatitis c december recorded writedown million part review otherthantemporary impairment since quoted market price achillion less cost basis three consecutive quarters see note glaxosmithkline inc april granted gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan south korea taiwan received million milestone payment gsk us approval hepsera million milestone payment canadian approval hepsera aggregate million milestone payments commercial approvals hepsera japan south korea taiwan received aggregate million milestone payments gsk achievement gsk four consecutive quarters hepsera gross sales exceeding million achievement certain drug status china gsk full responsibility development commercialization hepsera territories upfront license fee approval milestones recorded deferred revenue total million million million recognized contract revenue respectively table contents gilead sciences inc notes consolidated financial statementscontinued million balance deferred revenue december expected amortized contract revenue remaining period supply hepsera gsk agreement approximately nine years addition gsk required pay us royalties net sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories began receiving royalties gsks sales hepsera first quarter recorded million million million royalty revenues respectively result acquisition myogen november assumed rights march license distribution supply agreements myogen gsk terms license agreement gsk received exclusive sublicense rights ambrisentan certain hypertensive conditions territories outside united states received upfront payment subject achievement specific milestones eligible receive additional milestone payments addition receive stepped royalties based net sales ambrisentan gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses ambrisentan gsk territories term license agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals ambrisentan united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development march received milestone payment million gsk validation emea marketing authorization application ambrisentan treatment pah milestone upfront license payments million recorded deferred revenue amortized contract revenue remaining period performance obligations agreement approximately eight years february ambrisentan received positive opinion european committee human medicinal products treatment pah marketed name volibris gsk upon approval terms license agreement distribution supply agreement assumed part acquisition myogen received exclusive rights market promote distribute flolan sterile diluent flolan united states april osi pharmaceuticals inc march granted osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc worldwide rights therapeutic uses macugen macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement osi responsible rd costs osi sublicensed rights macugen territories outside united states pfizer entered license agreement pfizer terms contained agreement osi entitled receive payments osi osi reaches certain milestones well royalties worldwide net sales macugen subject obligation make payments third parties relating royalties agreement osi expires upon later ten years first commercial sale product developed date last patent expires agreement december entered agreement osi fill finish macugen osi january osi received fda approval sale macugen united states february macugen approved european union june recognized million milestone payment osi relating first commercial sale macugen european union included contract revenue recorded contract revenue million million million respectively connection clinical supplies provided osi milestones achieved osi table contents gilead sciences inc notes consolidated financial statementscontinued astellas pharma inc entered agreement astellas pharma inc astellas successor fujisawa usa inc related rights market ambisome terms agreement amended astellas responsible promotion ambisome united states canada exclusive marketing rights ambisome rest world subject obligation pay royalties astellas connection sales significant markets asia including china india japan south korea taiwan connection us sales astellas purchases ambisome us manufacturing cost sales canada astellas purchases ambisome manufacturing cost plus specified percentage receive royalties equal astellass gross profits sale ambisome united states canada gross profits include deduction cost goods sold giving us current effective royalty rate approximately astellass net sales ambisome united states connection agreement recorded royalty revenues million million million respectively longterm obligations convertible senior notes april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes collectively notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual terms notes aggregate principal amount notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments notes may convertible based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may convertible based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may converted subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note conversion value exceeds may also deliver option cash common stock combination cash common stock conversion value excess notes converted connection change control may required provide makewhole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount notes plus accrued unpaid interest thereon december fair values notes notes approximately million million respectively based quoted market values concurrent issuance notes purchased convertible note hedges private transactions cost million cover subject customary antidilution adjustments million shares common stock strike prices correspond initial conversion prices notes market value per share common stock time conversion notes strike price applicable convertible note hedges entitled receive counterparties transactions cash shares common stock combination cash common stock option excess market table contents gilead sciences inc notes consolidated financial statementscontinued price common stock strike price convertible note hedges convertible note hedges terminate upon maturity related notes none related notes remain outstanding due conversion otherwise also sold warrants acquire million shares common stock subject customary antidilution adjustments private transactions received net proceeds million market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices maximum number shares common stock could issued us choose net share settle warrants million shares underlying share amount reserved potential future issuance warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates taken together convertible note hedges warrants intended reduce potential dilution upon future conversions notes effectively increasing initial conversion price per share notes per share notes net cost million convertible note hedges warrant transactions recorded stockholders equity choice settling convertible note hedges warrants cash shares stock contracts meet applicable criteria equity classification outlined eitf issue accounting derivative financial instruments indexed potentially settled companys stock cost convertible note hedges net proceeds sale warrants classified stockholders equity addition contracts classified stockholders equity indexed common stock accounted derivatives sfas also recorded deferred tax asset million apic effect future tax benefits related convertible note hedges accordance sfas eitf income tax consequences issuing convertible debt beneficial conversion feature contemporaneously closing sale notes portion net proceeds notes issuance proceeds warrant transactions used repurchase million shares common stock million stock repurchase program terms notes agreements require us comply certain covenants december compliance covenants credit facilities december entered agreement syndicate banks fiveyear million senior credit facility million facility consisted uncollateralized million term loan entered gilead biopharmaceutics ireland corporation gbic one whollyowned irish subsidiaries uncollateralized million revolving credit facility entered us parent company gilead sciences inc proceeds term loan used gbic december facilitate cash dividend distribution million us parent company part repatriation qualified foreign earnings provisions american jobs creation act ajca terms term loan minimum amount principal payment required repaid end calendar quarter beginning march five percent outstanding balance interest accrued rate libor plus tiered contractual rate basis points payable quarterly arrears gbic could prepay term loan together accrued interest prepaid principal time whole part without penalty premium us parent company another whollyowned subsidiary guarantors year ended december million term table contents gilead sciences inc notes consolidated financial statementscontinued loan principal repaid year ended december repaid million represented remaining amounts due term loan time term loan terminated terms revolving credit facility entered december interest accrued payable rate libor plus tiered contractual rate basis points payable quarterly arrears us parent company could prepay outstanding borrowings together accrued interest prepaid principal time whole part without penalty premium outstanding interest principal december would payable demand capacity revolving credit facility would increase maximum million term loan repaid ability irrevocably cancel unutilized portion revolving credit facility whole part proceeds obtained revolving credit facility expected used working capital capital expenditures general corporate purposes including issuance letters credit million one whollyowned subsidiaries guarantor december borrowings revolving credit facility january received waivers noncompliance total debt total capitalization financial covenants year ended december contained credit agreements underlying million credit facility acquisitionrelated iprd expenses billion recorded fourth quarter purchased iprd caused us comply financial covenants concurrent waiver prospectively amended credit agreements exclude iprd expenses recorded commencing october definition total consolidated stockholders equity used calculation total capitalization total debt total capitalization ratio contained credit agreements december entered amended restated credit agreement superseded existing revolving credit agreement syndicate banks increase credit facility billion amended restated credit agreement also includes subfacility swingline loans letters credit entered gbic us parent company terms amended restated credit agreement may borrow initially aggregate billion revolving credit loans loans amended restated credit agreement bear interest either libor plus margin ranging basis points basis points ii base rate defined amended restated credit agreement prepay outstanding borrowings time whole part without penalty premium outstanding interest principal would due payable december connection amended restated credit agreement us parent company entered agreement guaranteeing obligations gbic amended restated credit agreement expect use proceeds loans amended restated credit agreement working capital requirements general corporate purposes december million letter credit outstanding amended restated credit agreement required comply certain covenants amended restated credit agreement december compliance covenants table contents gilead sciences inc notes consolidated financial statementscontinued capital lease obligations future minimum payments capital lease obligations years ending december follows thousands total less amount representing interest total less current portion total longterm obligations commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases san dimas california durham north carolina westminister colorado seattle washington dublin area ireland london area united kingdom expire various dates leases ireland united kingdom years respectively rent subject increase fifth anniversary respective commencement dates many facility leases options renew also operating leases sales marketing administrative facilities europe canada australia various terms equipment leases include three corporate aircraft varying terms renewal options upon expiration lease term lease expense operating leases totaled approximately million million million aggregate noncancelable future minimum rental payments operating leases years ending december follows thousands thereafter legal proceedings may united states district court northern district california executed orders dismissing entirety prejudice fourth consolidated amended complaint associated purported class action lawsuit us chief executive officer chief operating officer chief financial officer former executive vice president operations executive vice president research development chief scientific officer senior vice president manufacturing senior vice president research alleging defendants violated federal securities laws specifically sections b table contents gilead sciences inc notes consolidated financial statementscontinued securities exchange act amended rule b promulgated securities exchange commission making certain alleged false misleading statements plaintiffs appealed dismissal november received subpoena united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva complied united states attorneys subpoena intend cooperate related government investigation also party various legal actions arose ordinary course business believe legal actions material adverse impact business consolidated results operations financial position commitments august result review terms existing corporate aircraft leases upon consideration various alternatives available us upon expiration entered agreements purchase three aircraft constructed delivery aggregate purchase price purchase agreements million december made deposits totaling million recorded noncurrent assets consolidated balance sheet future deposits due terms purchase agreements follows million million million million million million option terminate purchase agreements subject maximum payment fullyequipped price aircraft normal course business entered various firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated activities december consist following next five years million million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients million million million years ended december respectively stockholders equity stock repurchase program march board directors board authorized program repurchase common stock amount billion twoyear period open market private block transactions pursuant rule b plans privatelynegotiated purchases means including accelerated stock repurchase transactions similar arrangements april repurchased retired shares common stock per share aggregate million may june repurchased retired aggregate shares common stock average purchase price per share aggregate purchase price million stock repurchase program expires march intend make repurchases common stock program october board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar table contents gilead sciences inc notes consolidated financial statementscontinued arrangements december repurchased retired shares common stock per share aggregate million billion stock repurchase program remaining authorized amount stock repurchases may made stock repurchase program terminates december billion use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average original sales price per issued share excess amounts charged retained earnings accumulated deficit result stock repurchase reduced common stock apic million retained earnings million result stock repurchases reduced common stock apic million charged million retained earnings preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series designated shares series junior participating preferred stock potential issuance november rights agreement mellon investor services llc formerly known chasemellon shareholder services llc amended rights plan preferred stock outstanding december december rights agreement rights plan provides distribution preferred stock purchase right dividend share common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade common stock october october may board approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october third amendment clarifying amendment entered connection increase designated number shares series junior participating preferred stock potential issuance rights plan may stock option plans may stockholders approved adopted equity incentive plan amended may plan stock options nexstar pharmaceuticals inc nexstar triangle corus myogen stock option plans assumed result acquisitions nexstar triangle corus myogen converted options purchase common stock effective closing respective acquisitions plan broadbased incentive plan allows awards granted table contents gilead sciences inc notes consolidated financial statementscontinued employees directors consultants plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options generally vest five years exercisable period exceed contractual term ten years date stock options issued granted prices less fair value common stock grant date stock option exercises settled newly issued common stock plans previously authorized available pool shares may stockholders approved increase additional number shares common stock available issuance plan december total shares common stock authorized grant plan total shares common stock reserved issuance shares remaining available future grant plan following table summarizes activity stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands year ended december weighted weighted weighted average average average shares exercise price shares exercise price shares exercise price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weighted average grant date fair value options granted year total intrinsic value options exercised years ended december million million million respectively total fair value stock options vested years ended december million million million respectively december number options outstanding expected vest net estimated future option forfeitures accordance provisions sfas r weighted average exercise price aggregate intrinsic value million weighted average remaining contractual life years aggregate intrinsic value stock options outstanding stock options exercisable december billion billion respectively december weighted average remaining contractual life options outstanding stock options exercisable years respectively table contents gilead sciences inc notes consolidated financial statementscontinued following summary stock options outstanding stock options exercisable december options thousands options outstanding options exercisable weighted weighted options average options average range exercise prices outstanding exercise price exercisable exercise price total december million unrecognized compensation cost related stock options expected recognized estimated weighted average period years performance shares january granted performancebased share awards plan awards divided three tranches vesting performance measurement purposes subject achievement specified market performance goals relative predetermined peer group awards vest threeyear period actual number common stock ultimately issue calculated multiplying number performance shares payout percentage ranging performance shares vest committee subcommittee board directors determined achieved specified market performance goals fair value marketrelated component performance shares estimated grant date using monte carlo valuation methodology fair value performancerelated component performance shares equivalent grantdate fair value common stock stockbased compensation performance shares recognized expense requisite performance periods using straightline expense attribution approach reduced estimated forfeitures recognized million stockbased compensation expense relating performance shares weightedaverage grantdate fair value performance shares per share december none performance shares vested million unrecognized compensation cost related nonvested performance shares expected recognized estimated weighted average period years january granted additional performancebased share awards terms substantially similar awards granted except single threeyear performance measurement vesting period restricted stock awards granted restricted stock awards one nonemployee directors plan lieu stock options customarily provided compensation nonemployee directors fair value restricted stock awards based fair value common stock date grant restricted stock shares vest six months date grant also granted restricted stock awards certain employees plan vesting awards subject achievement specified performance goals table contents gilead sciences inc notes consolidated financial statementscontinued following summary activity relating nonvested restricted stock awards year ended december weighted average grant date fair shares value nonvested january granted forfeited vested nonvested december weightedaverage grantdate fair value restricted stock awards granted respectively total fair value shares vested years ended december million million million respectively employee stock purchase plan employee stock purchase plan amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair value common stock offering date purchase date twoyear lookback feature espp causes offering period reset fair value common stock purchase date less original offering date espp purchases employees settled newlyissued common stock espps previously authorized available pool shares may stockholders approved amendments espp increase number shares authorized reserved issuance espp additional shares common stock extend term espp additional ten years january shares issued espp million total shares common stock reserved issuance espp shares remaining available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years stockbased compensation january adopted provisions sfas r requires sharebased payments employees directors including grants stock options recognized consolidated statements operations based fair values table contents gilead sciences inc notes consolidated financial statementscontinued table summarizes stockbased compensation expense sfas r thousands except per share amounts year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense included net income loss stockbased compensation expense included net income loss per share basic diluted year ended december capitalized million million stockbased compensation costs inventory respectively stockbased compensation recognized expense requisite service periods consolidated statements operations using graded vesting expense attribution approach nonvested stock options granted prior adoption sfas r using straightline expense attribution approach stock options granted adoption sfas r stockbased compensation expense related stock options recognized adoption sfas r based awards ultimately expected vest gross expense reduced estimated forfeitures sfas r requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption sfas r pro forma information required sfas included forfeitures occurred result adoption sfas r recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements operations rather apic table contents gilead sciences inc notes consolidated financial statementscontinued pro forma information sfas table presents net income basic diluted net income per share compensation cost stock option plans espp determined based estimated fair value awards plans grant purchase date accordance sfas thousands except per share amounts year ended december net incomeas reported add stockbased employee compensation expense included reported net income net related tax effects deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income net income per share basicas reported basicpro forma dilutedas reported dilutedpro forma valuation assumptions fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life connection adoption sfas r refined methodologies used derive valuation model assumptions calculate estimated fair value awards used following assumptions year ended december expected volatility stock options espp expected life years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted prior adoption sfas r calculated using multiple option approach fair value stock options granted beginning january calculated using single option approach table contents gilead sciences inc notes consolidated financial statementscontinued prior adoption sfas r used historical stock price volatility connection blackscholes option valuation model connection adoption sfas r determined blend historical volatility along implied volatility traded options common stock better reflection expected volatility expected life stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected life based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts comprehensive income loss comprehensive income loss comprises net income loss certain changes stockholders equity excluded net income loss changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statement stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized gain loss related availableforsale securities net tax provision benefit respectively net unrealized gain loss related cash flow hedges net tax benefit provision respectively reclassification adjustments net tax benefit respectively comprehensive income loss balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized gain availableforsale securities net unrealized loss cash flow hedges cumulative foreign currency translation adjustment accumulated comprehensive income loss table contents gilead sciences inc notes consolidated financial statementscontinued disclosures segments enterprise related information operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment major products truvada atripla viread emtriva hepsera ambisome together accounted substantially total product sales three years ended december similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december hiv products truvada atripla viread emtriva total hiv products hepsera ambisome total product sales following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner year ended december united states outside united states switzerland france spain united kingdom italy germany european countries countries total revenues outside united states total revenues december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes revenues customers individually accounted total revenues total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp f hoffmannla roche ltd amount less income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income million million million respectively cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately billion million december respectively residual us tax liability amounts remitted would approximately million million december respectively difference provision income taxes amount computed applying us federal statutory income tax rate income loss provision income taxes follows thousands year ended december income loss provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates purchased inprocess rd expenses research credits net unbenefitted stock compensation benefit qualified foreign earnings repatriation benefitted losses provision income taxes table contents gilead sciences inc notes consolidated financial statementscontinued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands december deferred tax assets convertible note hedges net operating loss carryforwards stockbased compensation capitalized intangibles research tax credit carryforwards depreciation related reserves accruals currently deductible net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance increased decreased million million million years ended december respectively concluded based standard set forth sfas likely realize benefit deferred tax assets related certain state net operating loss tax credit carryforwards released million valuation allowance would credited goodwill december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards expire various dates utilized also federal tax credit carryforwards approximately million expire utilized addition state net operating loss tax credit carryforwards approximately million million respectively valuation allowance million provided state net operating loss tax credit carryforwards expire various dates respectively utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization deferred tax assets relating tax benefits employee stock option grants reduced reflect exercises exercises resulted tax deductions excess previously recorded benefits based option value time grant additional tax benefits credited apic pursuant sfas r table contents gilead sciences inc notes consolidated financial statementscontinued october ajca signed law ajca allowed deduction certain qualified foreign earnings repatriated defined ajca elected apply provision qualifying earnings repatriation earnings repatriation resulted onetime tax benefit approximately million included reversal deferred tax liability previously accrued unremitted foreign earnings million december file federal state foreign income tax returns many jurisdictions united states abroad us federal california income tax purposes statute limitations remains open years inception due utilization net operating losses relating prior years income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years franchise tax board california tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions believe positions comply applicable laws periodically evaluate exposures associated tax filing positions recorded liabilities related uncertain tax positions accordance fin believe items currently pending material adverse effect consolidated financial statements although adverse resolution one items period could material impact results operations period prior adoption fin recorded liabilities related uncertain tax positions based upon sfas accounting contingencies december total federal state foreign unrecognized tax benefits million including interest million total unrecognized tax benefits million recognized would reduce effective tax rate period recognition permitted provisions fin continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statement operations respect unrecognized tax benefits currently unable make reasonably reliable estimate period cash settlement respective taxing authorities following rollforward total gross unrecognized tax benefit liabilities year ended december thousands balance january tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance december table contents gilead sciences inc notes consolidated financial statementscontinued deferred compensation plans maintain one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employees first contributions annual maximum match starting january contributed employees first contributions annual maximum match total matching contribution expense gilead plan million million million maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers may contribute annual salaries annual bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates available plan receive deferred compensation payment quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted total revenues gross profit product sales total costs expenses net income loss net income loss per sharebasic n et income loss per sharediluted fourth quarter recognized billion charge purchased iprd associated acquisitions third quarter recognized million charge purchased iprd associated acquisition table contents gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions table contents